Lab workup · Full case

Abnormal LFTs

BSG 2018 NICE NG49

>3× ULNALT/AST significant elevation threshold

>17 μmol/LBilirubin upper limit of normal

<35 g/LAlbumin hypoalbuminaemia threshold

>1.2 INRINR hepatic synthetic dysfunction

One goFull liver screen + USS + FIB-4 — do not repeat and wait

>10× ULNALT acute hepatitis / DILI threshold

FIB-4 >2.67High risk — hepatology referral (threshold per local pathway)

Suspected cancer pathway referralLiver mass: urgent USS (NG12) · new lesion on cirrhosis surveillance: local HCC pathway

📋 Clinical Stem — Abnormal LFT Result in Primary Care

A patient presents to discuss an abnormal liver function test result found incidentally or on routine screening.

"Mr Patel, a 52-year-old finance manager, attends to discuss blood results taken three weeks ago by the practice nurse during a health check. His ALT is 87 U/L (normal <45), his GGT is 112 U/L, and his ALP is 140 U/L. He mentions his GP 'just said the liver tests were a bit off' but did not explain what that meant. He drinks 'maybe 20 units a week' and his BMI is 31. He is on atorvastatin 40 mg, metformin 500 mg twice daily, and ibuprofen PRN for back pain. He appears well and has no jaundice."

This stem represents the most common LFT scenario in UK general practice: the incidental or screening abnormality requiring pattern recognition, systematic workup, and patient-centred explanation. The same consultation structure applies whether the elevation is mild and likely benign, or severe and suggesting liver failure. Adapt the urgency and management based on the pattern and severity of derangement.

Scenario A — MASLD/Metabolic Middle-aged, overweight patient, mild ALT/GGT elevation, metabolic risk factors (T2DM, hypertension, dyslipidaemia), no alcohol excess — classic MASLD presentation requiring lifestyle intervention and fibrosis assessment with FIB-4.

Scenario B — Alcohol-related Patient with high alcohol intake, raised GGT disproportionate to ALT, AST:ALT ratio >2:1, macrocytosis, thrombocytopenia — ARLD requiring AUDIT-C, fibrosis staging, and sensitive brief intervention without moralising.

Scenario C — Drug-induced (DILI) Patient started on a new medication (statin, antibiotics, herbal remedies) 4–12 weeks ago with new hepatocellular or cholestatic pattern — requires RUCAM causality assessment, drug cessation decision, and monitoring.

Scenario D — Cholestatic pattern Raised ALP and GGT with normal or mildly raised ALT in an older patient, possibly with pruritus — primary biliary cholangitis (especially women), gallstone disease, or pancreatic malignancy must be excluded urgently with USS.

Scenario E — Acute hepatitis Unwell patient, ALT >10× ULN, jaundice, RUQ pain — viral hepatitis (A, B, E), acute alcoholic hepatitis, or acute DILI requiring same-day assessment and possible emergency admission.

Key variables to adapt for: Degree of elevation (mild <3×, moderate 3–10×, severe >10× ULN), pattern (hepatocellular vs cholestatic vs mixed vs isolated bilirubin), symptoms (well vs unwell), alcohol intake, medication list including herbals, risk factors for viral hepatitis, BMI and metabolic syndrome, family history of liver disease.

Steps:

Step 1

History Taking — Open Question First · Targeted Questions · ICE · Psychosocial Context

▲collapse

The consultation begins before the question is asked. The patient has received a result they may not understand, and their anxieties about what it means — cancer, cirrhosis, the need to stop drinking — will shape everything. Acknowledge the result exists, let them speak first, then systematically characterise the pattern: hepatocellular vs cholestatic, severity, likely aetiology, and whether the patient is currently well or deteriorating. Every question must serve the differential or change the management plan.

🎓 Consultation opener — use existing information first

"I can see you have come to discuss your blood results — the liver tests that came back a few weeks ago. Before I go through them, I would love to hear from you first: what has been on your mind since you got that message?"

Opening with the patient's frame of reference scores Relating to Others (agenda-setting) and Global Skills (structure) before any clinical questioning. Asking what they already know avoids insulting patients who have researched it, and identifies catastrophising that needs addressing. Asking for their results again without signalling you have read them costs 1–2 RO marks immediately.

1A — Start with an open question: let the patient lead, then move to targeted questions

Question to ask	Why it matters clinically	Changes what?
🍚 OPEN QUESTION — always start here"What has been going through your mind since you heard your liver tests were abnormal?"	Elicits the patient's illness model, hidden fears (cancer, cirrhosis, need to stop drinking), and sets collaborative tone. Also reveals how the result was communicated — a poorly communicated result damages trust and drives anxiety.Scores: Relating to Others (agenda), Global Skills (ICE). Lets the patient give you the history they think is relevant before you filter it.	Patient agendaDifferential
Jaundice and cholestasis"Have you noticed any yellowing of your skin or eyes, dark urine, pale stools, or itching?"	Jaundice, dark urine, and pale stools indicate cholestasis — urgently changes the pathway. Pruritus without jaundice can be the presenting feature of primary biliary cholangitis or obstructive jaundice.Pruritus due to cholestasis is characteristically worse at night and on the palms and soles.	UrgencyDDxReferral
Systemic symptoms"Any fatigue, weight loss, fever, night sweats, or loss of appetite recently?"	Constitutional symptoms raise the probability of malignancy (HCC, metastatic disease, lymphoma), granulomatous disease (sarcoidosis, TB), or active viral hepatitis. Weight loss plus raised ALP warrants urgent suspected cancer pathway referral.Unexplained weight loss of more than 5% in 6 months is a red flag requiring cancer pathway consideration.	Suspected cancer pathway referralDDxReferral
Right upper quadrant pain"Any pain or discomfort in the right side of your abdomen, or after eating fatty foods?"	RUQ pain post-prandially suggests gallstone disease. Constant RUQ pain or a palpable mass raises concern for hepatic malignancy. Colicky pain radiating to the right shoulder blade is classic biliary colic.Charcot's triad (RUQ pain, fever, jaundice) = cholangitis — a surgical emergency requiring 999.	UrgencyDDxImaging
Alcohol history"Can I ask about your alcohol intake? In a typical week, on how many days do you drink, and roughly how much would you have on a drinking day?"	Alcohol is the most common modifiable cause of raised LFTs in UK adults. AST:ALT ratio >2:1 with a disproportionately raised GGT supports, but does not prove, alcohol aetiology. Quantify in units — 14 units/week is the recommended maximum. Must ask directly and non-judgementally.MCV macrocytosis and thrombocytopenia support alcohol-related liver disease. AUDIT-C is validated in primary care.	AetiologyManagementBehaviour change
Medications including supplements"Can you tell me everything you are taking — including any over-the-counter medicines, herbal or traditional remedies, nutritional supplements, or anything you have bought online?"	Drug-induced liver injury (DILI) is the most common cause of acute liver failure in the UK. NSAIDs, statins, antibiotics (co-amoxiclav, nitrofurantoin), herbal remedies (green tea extract, kava, weight-loss supplements), and Chinese traditional medicines are frequent culprits. RUCAM scoring requires a detailed chronological medication list.Herbal and traditional medicines are systematically under-reported. Ask specifically about weight-loss products and supplements.	DILI aetiologyStop drug
Viral hepatitis risk factors"Have you ever injected drugs? Had a tattoo or piercing? Had unprotected sex with new partners? Received a blood transfusion before 1992? Travelled to Asia, Africa, or Eastern Europe?"	Hepatitis B and C are chronically under-diagnosed in the UK. Hep B: sexual transmission, vertical transmission (South Asian, sub-Saharan African communities). Hep C: IVDU (main UK route), pre-1992 transfusion. Hep A and E: travel and shellfish. Hep E is increasingly recognised in the UK via pig and pork exposure.Hep C is now curable — identifying it is a significant health gain. Do not assume risk factors by appearance.	Viral aetiologySerologyReferral
Metabolic risk factors"Do you have diabetes, high blood pressure, or high cholesterol? How would you describe your diet and physical activity level?"	Metabolic dysfunction-associated steatotic liver disease (MASLD — formerly NAFLD) is now the most prevalent chronic liver disease in the UK, affecting approximately 25% of adults. It is strongly associated with type 2 diabetes, obesity, dyslipidaemia, and hypertension. Lifestyle factors directly determine management.MASLD can progress to cirrhosis even in non-obese patients with metabolic syndrome — do not reassure on BMI alone.	MASLDLifestyle RxFIB-4
Autoimmune history"Have you been diagnosed with any autoimmune conditions — thyroid disease, coeliac disease, inflammatory bowel disease, rheumatoid arthritis, or psoriasis?"	Autoimmune hepatitis (AIH) is associated with other autoimmune conditions, is more common in women, and can present with acute hepatitis or be found incidentally. Primary biliary cholangitis (PBC) is almost exclusively in women with comorbid autoimmune disease. Coeliac disease causes transaminase elevation that normalises on a gluten-free diet.AIH can be rapidly progressive — refer to hepatology before any corticosteroid. Check anti-smooth muscle antibody (ASMA) and ANA with immunoglobulins; anti-LKM1 if AIH is still possible.	AIH / PBCAutoimmune screenReferral
Family history"Has anyone in your family had liver disease, liver cancer, or any hereditary conditions?"	Wilson's disease (copper metabolism, young patients, neuropsychiatric features), haemochromatosis (iron overload, Northern European, men aged 30–60), alpha-1 antitrypsin deficiency, and familial hyperlipidaemia are hereditary causes requiring specific testing and genetic counselling.Haemochromatosis is the most common inherited metabolic disorder in Northern Europeans — serum ferritin and transferrin saturation are the screening tests.	HereditarySpecialist tests
Timing and context"Do you know when these tests were taken and whether this is the first time the liver results have been abnormal?"	A new abnormality needs investigation; a persistently mildly abnormal result that has been present for years may have different (lower) urgency. If the result was taken during a new medication introduction, DILI timing is key (RUCAM). Knowing it has been missed for two years changes both the aetiology probability and patient expectations.Check the GP record before the consultation — comparing to previous results is basic standard of care and prevents clinical error.	TimingUrgency

1B — Red flags: must not miss · must ask · must act

🚨

Red Flags — act before continuing history

Red flag	Why dangerous	Action
Jaundice + confusion / asterixis (hepatic flap)	Hepatic encephalopathy — indicates acute or acute-on-chronic liver failure. Ammonia accumulation causes cerebral oedema and death if untreated.	999 / A&E now
Haematemesis or melaena with known or suspected liver disease	Oesophageal or gastric varices — a life-threatening complication of portal hypertension. Mortality per bleed is 15–20% without banding. Requires immediate resuscitation and endoscopy.	999 / A&E now
Rapidly progressive jaundice + coagulopathy (INR >1.5) + any encephalopathy	Acute liver failure — paracetamol overdose, acute viral hepatitis, Budd-Chiari. Time-critical; may need transplant listing within hours. King's College criteria must be assessed urgently.	999 / A&E now
Fever + jaundice + RUQ pain (Charcot's triad)	Ascending cholangitis — biliary sepsis with potential for rapid cardiovascular collapse. Gram-negative sepsis risk. Requires IV antibiotics and urgent ERCP.	999 / A&E now
Weight loss >5% in 6 months + raised ALP or abdominal mass	Hepatocellular carcinoma, cholangiocarcinoma, pancreatic cancer with biliary obstruction, or metastatic disease. ALP is raised by bone metastases as well as biliary pathology — must distinguish.	Suspected cancer pathway referral
ALT or AST >10× ULN in an unwell patient	Indicates acute hepatocellular injury — acute viral hepatitis (A, B, E, EBV, CMV), acute DILI, ischaemic hepatitis, acute alcohol-related hepatitis, or autoimmune hepatitis flare. Rapid synthetic dysfunction can follow within days.	Same-day assessment
New ascites or peripheral oedema with raised LFTs	Portal hypertension with decompensation — indicates advanced cirrhosis or right heart failure. Spontaneous bacterial peritonitis (SBP) has a 30% mortality rate without prompt treatment.	Same-day assessment

🛡️

Safeguarding Considerations — Consider in Every Consultation

Abnormal LFTs can be a marker of harm. Alcohol-related liver disease may reflect harmful alcohol use that conceals domestic violence, financial abuse, or exploitation. In young patients, raised LFTs with vague histories should prompt enquiry about substance misuse in a safeguarding context, including coercion by adults in positions of trust.

🏠 Domestic Abuse / Intimate Partner Violence

Harmful alcohol use is both a risk factor for and consequence of domestic abuse
Ask sensitively about home circumstances if alcohol-related liver disease is suspected
Unexplained physical injuries with LFT abnormality may conceal physical abuse
Use HARK or HITS validated screening tools if concern arises

👴 Older Adults / Carer-related Concern

Alcohol misuse in older adults is frequently missed and may represent self-neglect or isolation
An older adult with abnormal LFTs and unexplained weight loss — consider financial exploitation and medication mismanagement by carers
Consider capacity assessment if patient is confused and has jaundice — hepatic encephalopathy impairs decision-making
Malnutrition (low albumin) with raised LFTs may indicate neglect rather than primary liver disease

🧒 Children in the Household

Significant alcohol-related liver disease in a parent requires consideration of the impact on dependent children
Parental alcohol use disorder is a recognised child protection risk factor — Children Act 1989 duties apply
Hepatitis B or C diagnosis in a parent necessitates referral of household contacts for testing and vaccination
Consider referral to social care if chaotic alcohol use with young children in the household

💊 Self-Harm / Substance Misuse Risk

Paracetamol overdose (self-harm) causes acute liver failure — always ask about overdose in young patients with acute elevated transaminases
IVDU-related hepatitis C — explore whether the patient is in contact with addiction services; needle exchange referral may be appropriate
Concealed alcohol dependence may present with LFT abnormality without disclosure — use AUDIT-C and CAGE
Prescribed medication misuse can cause DILI

If a safeguarding concern is identified: Document clearly in the medical record, avoid dismissing concerns because the patient denies harm, discuss with the safeguarding lead or named nurse, and consider referral to children's or adult social care as appropriate. Your duty of care to any identified third party may override patient confidentiality under the Children Act 1989 and the Care Act 2014.

1C — PMH · FH · Drug history · Social history: management impact

🧬 PMH / FH — changes management

Factor	Why it matters	Management impact
Type 2 diabetes / obesity	Strongest risk factor for MASLD and MASLD-related cirrhosis; synergistic effect on fibrosis progression	FIB-4 score mandatory; lifestyle intervention priority; pioglitazone or vitamin E only via secondary care for advanced fibrosis (NG49)
Previous jaundice / liver disease	May indicate chronic liver disease misattributed to other causes or underinvestigated previously	Review old records; new abnormality in chronic disease requires re-investigation
Previous biliary surgery / cholecystectomy	Post-cholecystectomy syndrome; retained common bile duct stones; biliary stricture formation	Cholestatic pattern post-surgery → MRCP to exclude CBD stones or stricture
Coeliac disease	Raised transaminases (ALT 2–3× ULN) in ~40% of newly diagnosed coeliac disease; normalises on gluten-free diet	Check TTG-IgA if not recently done; liver abnormality resolves with gluten-free diet
Hypothyroidism	Can cause mild transaminase elevation due to myopathy-related AST release and direct hepatic effect	Check TSH; treat hypothyroidism first before attributing LFTs to liver disease
Haemochromatosis (FH)	Autosomal recessive; HFE gene C282Y mutation; males aged 30–60 with diabetes, arthralgia, bronze skin	Ferritin + transferrin saturation (>45% → HFE genotyping); family screening; venesection
Wilson's disease (FH / young patient)	Autosomal recessive copper metabolism disorder; presents aged 5–35 with liver disease and neuropsychiatric features	Serum caeruloplasmin + slit-lamp exam; refer hepatology urgently if suspected
Known viral hepatitis B or C	Chronic infection with ongoing replication changes management goals entirely	Hepatology co-management; antiviral therapy; HCC surveillance with 6-monthly USS ± AFP (NG50)

💊 Drug history · Social history — clinical impact

Factor	Why it matters	Management impact
Statins	Cause transaminase elevation in ~3% of patients; rarely cause true DILI; more commonly transient benign elevation	If <3× ULN: continue (transaminases at baseline, within 3 months of starting or changing and at 12 months). Persistent unexplained >3× ULN: investigate and withhold pending review — not automatic permanent discontinuation; consider cautious reintroduction once resolved (NICE NG238). Statins are safe in MASLD and ARLD — do not stop without cause.
NSAIDs (ibuprofen, diclofenac)	Hepatotoxic particularly with long-term use; diclofenac causes characteristic hepatocellular DILI pattern	Stop NSAID if possible; switch to paracetamol (reduce the dose with risk factors: commonly max 3 g/day; some SPCs advise 2 g/day in chronic heavy alcohol use — check the SPC)
Herbal / traditional remedies	Green tea extract, kava, black cohosh, Ayurvedic and Chinese traditional medicines — common under-reported causes of severe DILI and acute liver failure	Stop all herbal products immediately; report to Yellow Card scheme; RUCAM causality assessment
Alcohol intake (social)	Quantify using AUDIT-C; 14 units/week lower-risk limit (not a safe limit). AST:ALT >2:1 + elevated GGT supports ARLD (not diagnostic alone)	Brief intervention if hazardous; structured ARLD programme if dependent; fibroscan for fibrosis staging; 6 weeks abstinence then repeat LFTs
Occupation	Healthcare workers: hepatitis B risk; farmers and vets: leptospirosis; industrial chemical exposure	Occupational exposure may determine hepatitis B vaccination status and specific serology required
Travel history	Hepatitis A (developing world, shellfish), hepatitis E (South Asia, North Africa, pig exposure), schistosomiasis (sub-Saharan Africa)	Hepatitis A and E serology; stool PCR for parasites; specialist tropical medicine input if needed
Sexual history	Hepatitis B sexual transmission; hepatitis A in MSM outbreaks; HIV-associated liver disease	HIV test plus hepatitis B serology; partner notification if positive; PrEP discussion
Exercise / muscle injury	Strenuous exercise or rhabdomyolysis raises AST (muscle enzyme) — can mimic liver disease if CK not checked	Check CK alongside LFTs; if CK elevated plus AST raised plus ALT normal = muscle origin, not liver

1D — ICE: Ideas · Concerns · Expectations — in every consultation, not just SCA

A patient told their "liver tests are abnormal" without further context will construct their own narrative — usually the worst-case one. Their Ideas (cancer? cirrhosis? the drinking has caught up with them?) will determine whether they engage with the investigation plan or disengage. Their Concerns (will they lose their job? driving licence? have to tell their family?) will determine adherence to lifestyle advice. Their Expectations (a scan? a referral? immediate treatment?) must be elicited before the plan is offered, or shared decision-making is impossible. ICE in LFT consultations also serves to uncover the alcohol story the patient is reluctant to tell.

💭 Ideas

"When you found out the liver tests were abnormal, what did you think might be causing it?"

Uncovers whether the patient has already attributed it to alcohol, medication, diet, or fears cancer. A patient who says "I thought it was probably the drinking" opens a different conversation than one who says "I have no idea, I feel completely fine" — one needs Brief Intervention, the other needs reassurance and explanation of common benign causes.

😟 Concerns

"What is your biggest worry about this result? Is there something specific you have been anxious about?"

The hidden agenda is almost always cancer, cirrhosis, or something catastrophic. Naming it — "a lot of people worry this could mean something serious, like cancer" — deflates the unspoken fear and allows a focused, reassuring response. Failing to address the hidden concern means the patient leaves with the same anxiety even if the medical plan is appropriate.

🎯 Expectations

"What were you hoping we might be able to do today — or what were you expecting might happen next?"

Some patients expect an urgent scan; others expect immediate referral; others want to be told it is nothing. Eliciting the expectation before presenting the plan allows you to validate the reasonable parts, negotiate the unreasonable parts, and avoid leaving patients feeling dismissed if their expectation is not met.

1E — Psychosocial context: the person behind the LFTs

Liver disease is uniquely entangled with psychosocial context. Alcohol-related liver disease — the UK's leading cause of liver-related death in working-age adults — is driven by stress, socioeconomic deprivation, mental health comorbidity, and social isolation. MASLD is driven by food insecurity, time poverty, sedentary work, and the obesogenic environment. Understanding the patient's social world determines whether lifestyle advice is realistic or insulting, and whether treatment engagement is achievable.

🍷 Alcohol and Stress

Stress-induced alcohol use is the most common psychosocial driver of ARLD in UK primary care. High-pressure occupations (finance, law, healthcare, hospitality), bereavement, divorce, and job loss are precipitating contexts. Alcohol is often the patient's primary coping mechanism.

"A lot of people find they are drinking more when things are difficult. How have things been for you recently at home or at work?"

If stress is driving alcohol use, abstinence alone without addressing the stressor will fail. Mental health support, occupational referral, and alcohol liaison are part of the plan.

🏙️ Socioeconomic Deprivation

Liver disease shows the steepest socioeconomic gradient of any organ-specific disease in England. ARLD mortality is disproportionately higher in deprived areas; MASLD is driven by food deserts, shift work, and inability to afford gym membership or healthy food.

"I want to make sure any advice I give is actually realistic for your situation. What does your typical week look like — meals, activity, work patterns?"

Prescribe lifestyle advice that is free, accessible, and realistic. Referral to a dietitian, social prescribing link worker, or food bank signposting may be more useful than a generic diet sheet.

🧠 Mental Health Comorbidity

Depression and anxiety are bidirectionally linked with both ARLD (alcohol as self-medication) and MASLD (bidirectional neuroendocrine and inflammatory links). Antidepressants (particularly mirtazapine, tricyclics) can raise transaminases. Patients with serious mental illness have higher rates of liver disease and lower rates of investigation.

"How has your mood been recently? Some people find liver problems linked to alcohol can also affect how they are feeling emotionally."

PHQ-9 / GAD-7 scoring is appropriate. Mental health treatment is a prerequisite for successful alcohol harm reduction in many patients.

👪 Family and Social Support

Liver disease — whether alcohol-related, viral, or metabolic — affects the entire family unit. Patients with ARLD often conceal drinking from partners; hepatitis B or C diagnoses carry stigma and affect relationships, sexual activity, and partner notification. Social isolation is a key risk factor for continued harmful alcohol use.

"Is there anyone at home who knows what has been going on with these results? Do you feel you have support around you?"

Involving a supportive family member (with consent) significantly improves engagement with ARLD programmes. Hepatitis B and C partner notification is a clinical and public health duty.

🏢 Work and Occupation

ARLD in high-pressure occupations often involves corporate drinking culture. MASLD is particularly associated with sedentary desk work and long hours preventing exercise and home cooking. A diagnosis of liver disease — particularly cirrhosis — has significant occupational implications including driving (HGV/PSV licence) and some regulated professions.

"How would any changes to your health — or to your drinking — affect your work? Is drinking part of your working culture?"

Occupational health referral may be appropriate. DVLA guidance requires notification if cirrhosis with complications is confirmed — this is a doctor's duty to advise clearly.

🌎 Cultural and Ethnic Background

Hepatitis B prevalence is significantly higher in South Asian, sub-Saharan African, East Asian, and Eastern European communities due to vertical transmission and limited childhood vaccination in countries of origin. Stigma around hepatitis diagnoses in these communities can prevent disclosure and treatment. MASLD has a higher prevalence in South Asian patients at lower BMI thresholds.

"I want to make sure I understand your background. Have you or your family had any liver or hepatitis tests before, perhaps in another country?"

MASLD fibrosis risk in South Asian patients is higher at BMI >23 kg/m² (Asian-specific threshold). Hepatitis B family screening is a clinical and public health priority in affected communities.

🎓 SCA Checkpoint — Step 1TasksRelating to OthersGlobal Skills

Key phrases that score

"Before I go through the results, can I ask what has been on your mind since you got that message?"

"When you found out your liver tests were slightly abnormal, what did you think might be causing it?"

"In a typical week, on how many days do you drink alcohol, and roughly how much on a drinking day?"

"Are you taking anything else — any over-the-counter medicines, herbal remedies, supplements — anything at all?"

Deductions (examiner flags)

Jumping straight to explaining the result without eliciting ICE
Not asking about alcohol intake when LFTs are raised
Asking about medications without including herbal and OTC products
Not asking about symptoms of decompensation (jaundice, confusion, bleeding)
Giving lifestyle advice without exploring psychosocial barriers
Not naming the patient's concern (cancer or cirrhosis fear) if signalled

🔴 Red — failing

No open question. No ICE. Jumps to explanation without hearing the patient. Does not ask about alcohol or medications. Misses red flag symptoms.

🟠 Amber — borderline

Asks some targeted questions but history incomplete. Asks about alcohol but not quantified. ICE partly explored — only Ideas, not Concerns or Expectations. Psychosocial context skipped.

🟢 Green — passing

Open question first. Full ICE explicitly named. Alcohol quantified in units. Full medication screen including herbals. Psychosocial context explored. Red flags addressed. Data gathering complete by 6–7 minutes.

Step 2

Triage Engine — Emergency · Urgent · Routine

▲collapse

LFT abnormalities span the full triage spectrum — from a mildly raised ALT in a well patient (routine) to acute liver failure with encephalopathy (immediately life-threatening). The triage decision is primarily based on: (1) is the patient systemically well or unwell? (2) what is the degree of elevation? and (3) are there features of hepatic decompensation? Any feature of decompensation mandates same-day or emergency assessment regardless of the transaminase level.

🔴 Emergency

999 or Same-Day Hospital

Call 999 / A&E now

Hepatic encephalopathyConfusion, asterixis, drowsiness with raised LFTs — acute liver failure. 999 immediately.
Haematemesis or melaena with liver diseaseVariceal bleeding — mortality 15–20% per episode. Resuscitation and urgent endoscopy.
Charcot's triad: fever + jaundice + RUQ painAscending cholangitis — biliary sepsis. IV antibiotics and urgent ERCP.
Acute liver failure (INR >1.5 + any encephalopathy)King's College criteria assessment needed. Possible transplant listing within hours.
Suspected paracetamol overdose with raised LFTsN-acetylcysteine must start within 8–10 hours of ingestion for maximum efficacy.

🟠 Urgent

Same-Day GP / Urgent Assessment

Days to 2 weeks

ALT or AST >10× ULN in a well patientSame-day GP review. Acute viral hepatitis, acute DILI, ischaemic hepatitis. Check INR, bilirubin, albumin urgently.
New jaundice without encephalopathySame-day assessment with urgent liver USS and coagulation screen. Aged 40+ → suspected cancer pathway referral for pancreatic cancer (NG12).
New ascites with raised LFTsUrgent secondary care referral — decompensated cirrhosis. Diagnostic ascitic tap to exclude SBP.
Cholestatic pattern + weight loss or abdominal massSuspected cancer pathway referral — pancreatic or biliary malignancy must be excluded.
Raised LFTs + INR >1.2 (not on warfarin)Synthetic dysfunction — indicates significant hepatocellular damage. Same-day review to determine trajectory.
Acute DILI pattern — drug started 4–12 weeks agoStop the suspected drug where safe; check bilirubin, INR, albumin and glucose; recheck at 4–6 weeks. Jaundice, coagulopathy, encephalopathy or rapid worsening → same-day assessment.

🟢 Routine

Manage in Primary Care

GP practice

ALT/AST <3× ULN, well patient, likely metabolic aetiologySend the full liver screen, USS and FIB-4 now — do not just repeat and wait. Recheck LFTs 4–6 weeks after stopping a suspect drug or alcohol.
Isolated raised GGT, no other abnormalitiesExplore alcohol intake and medications. GGT is a sensitive but non-specific marker — confirm aetiology before investigating further.
Isolated raised ALP in a young patient, no cholestatic symptomsCheck GGT (if GGT normal, ALP is from bone not liver — no liver investigation needed). Common in pregnancy (placental ALP).
MASLD on ultrasound, mildly raised ALT, BMI >30, no fibrosis markersLifestyle and CV risk management, FIB-4 score; repeat fibrosis assessment every 2–3 years if low risk. FIB-4 <1.3 = low fibrosis risk — manage in primary care.
Known ARLD, currently abstinent, LFTs improving6-week repeat LFTs, ARLD programme engagement, FIB-4 reassessment at 6 months.

🎓 SCA Checkpoint — Step 2TasksRelating to OthersGlobal Skills

Key phrases that score

"Given how your results look and how you are feeling, I do not think this is an emergency — but I do want to make sure we investigate this properly."

"There are some symptoms that would mean you would need to go to hospital straight away — have you noticed any yellowing of your skin or eyes, or any confusion?"

"Some patterns of liver test results need urgent investigation — I will explain where yours fits."

Deductions (examiner flags)

Failing to ask about symptoms of decompensation before deciding triage level
Treating a >10× ULN elevation as routine and scheduling 8-week repeat
Not advising the patient what symptoms to present to A&E with immediately
Missing the suspected cancer pathway for cholestatic pattern with constitutional symptoms

🔴 Red — failing

Does not differentiate urgency levels. Treats all LFT abnormalities identically. Misses red flags for decompensation.

🟠 Amber — borderline

Asks about some decompensation features but incomplete. Correct triage level but safety-netting for emergency presentation not given.

🟢 Green — passing

Explicitly asks about encephalopathy, jaundice, bleeding, and ascites. Correctly stratifies urgency. Tells patient clearly what to do if symptoms develop. Names the suspected cancer pathway if cancer suspected.

Step 3

Do I Need This Examination?

▲collapse

Physical examination in abnormal LFTs narrows the differential, identifies decompensation, and quantifies the severity of any underlying liver disease. A well patient with mildly raised LFTs may have a near-normal examination. A patient with advanced chronic liver disease will show stigmata. Every finding changes either the diagnosis or the urgency. The examination must be systematic and documented — medicolegally, unexplained hepatomegaly without USS referral is indefensible.

Examination	Why it matters	What finding changes management	Changes management?
Jaundice — eyes and skin	Jaundice usually becomes clinically detectable above about 40 μmol/L. Scleral icterus is more sensitive than skin yellowing.Pre-hepatic (haemolysis): pale conjunctivae plus jaundice. Post-hepatic (obstruction): dark urine, pale stools.	Any clinical jaundice → same-day review or A&E if unwell. Changes investigation priority to include biliary ultrasound urgently.	YES — urgency
Hepatomegaly — percussion and palpation	Smooth hepatomegaly: fatty liver (MASLD), viral hepatitis, cardiac failure (tender). Irregular hard hepatomegaly: malignancy. Liver shrinkage: cirrhosis.Measure span — >15 cm on percussion suggests hepatomegaly. Palpate from RIF upwards.	Hard irregular hepatomegaly → urgent USS and suspected cancer pathway referral. Tender smooth hepatomegaly with raised JVP → rule out right heart failure.	YES — pathology type
Splenomegaly	Indicates portal hypertension — a marker of clinically significant fibrosis or cirrhosis. Any palpable spleen is significant (spleen must be 3× normal size to be palpable).Splenomegaly plus raised LFTs plus thrombocytopenia = advanced portal hypertension until proven otherwise.	Palpable splenomegaly → urgent hepatology referral for cirrhosis assessment, varices screening (OGD), and HCC surveillance.	YES — referral trigger
Stigmata of chronic liver disease	Spider naevi (>5, above nipple line), palmar erythema, leuconychia, clubbing, Dupuytren's contracture (ARLD), parotid enlargement, gynaecomastia, testicular atrophy, caput medusae, asterixis (hepatic flap).Each stigma individually is non-specific; multiple stigmata together = advanced chronic liver disease until proven otherwise.	Multiple stigmata → urgent hepatology referral. Asterixis = encephalopathy → A&E immediately.	YES — diagnosis and urgency
Ascites — shifting dullness and fluid thrill	Ascites indicates decompensated liver disease, right heart failure, peritoneal malignancy, or nephrotic syndrome. In liver disease context, ascites = decompensation.Shifting dullness is positive if dullness shifts >2 cm with position change. Fluid thrill detects >2L ascites.	Clinical ascites → urgent same-day referral for diagnostic ascitic tap (exclude SBP), USS, and hepatology input.	YES — urgent referral
BMI, waist circumference, body habitus	BMI >30 is the single strongest clinical predictor of MASLD. Central adiposity (waist >94 cm men, >80 cm women) with normal BMI can also cause MASLD. Visceral fat is the driver of hepatic steatosis and fibrosis.Lean MASLD (BMI <25) occurs in 10–20% of MASLD patients, especially South Asian patients — do not exclude MASLD on BMI alone.	BMI >30 with metabolic features → FIB-4 score mandatory for fibrosis risk stratification even with mild LFT elevation.	YES — investigation pathway
Kayser-Fleischer rings (slit-lamp)	Golden-brown deposits at the corneal periphery — pathognomonic of Wilson's disease (copper deposition). Cannot be seen by naked eye. Present in >95% of Wilson's with neurological involvement.Wilson's disease presents between ages 5–35. Any young patient with unexplained liver disease needs caeruloplasmin and refer for slit-lamp.	Kayser-Fleischer rings confirmed → immediate hepatology referral for Wilson's disease work-up and initiation of copper chelation therapy.	YES — diagnosis changes
Cardiovascular examination (JVP, pedal oedema, murmurs)	Cardiac cirrhosis from chronic right heart failure (tricuspid regurgitation, constrictive pericarditis) causes congestive hepatopathy — raised JVP, pulsatile liver, oedema.A raised JVP with tender hepatomegaly and oedema is a cardiac cause of LFT abnormality until proven otherwise.	Signs of right heart failure with raised LFTs → echocardiogram and cardiology referral. Changes management completely from liver-focused to cardiac-focused.	YES — aetiology

🎓 SCA Checkpoint — Step 3TasksRelating to OthersGlobal Skills

Key phrases that score

"I would like to examine your tummy — I will be looking specifically at your liver and spleen, which are organs that can be affected when liver tests are abnormal."

"I am also going to look at your hands and eyes, as they can give us useful clues about how long the liver has been under stress."

"I would like to check your weight and waist measurement today — these are important for understanding what might be causing the abnormal results."

Deductions (examiner flags)

Failing to offer abdominal examination in a patient with raised LFTs
Not checking for jaundice clinically (scleral icterus) when bilirubin is raised
Missing BMI and waist measurement in a patient with suspected MASLD
Not linking examination findings to the investigative or management plan

🔴 Red — failing

Does not offer examination. Fails to link findings to differential. Does not look for signs of decompensation.

🟠 Amber — borderline

Examines abdomen but does not systematically check for chronic liver disease stigmata or cardiovascular examination.

🟢 Green — passing

Full abdominal exam including hepatomegaly, splenomegaly, ascites. Checks hands, eyes, and skin for stigmata. BMI and waist recorded. Explains findings to patient. Links each finding to next clinical step.

Step 4

Do I Need This Investigation?

▲collapse

Investigate, do not repeat and wait — send the non-invasive liver screen in one go. The degree of enzyme abnormality does not predict severity and normal LFTs do not exclude cirrhosis, so a repeat alone is reserved for a clear transient cause (recent illness, stopped drug). Send the standard liver aetiology screen with an ultrasound at the first visit (BSG 2018), identify the most likely aetiology from the history and examination, and stage the fibrosis. FIB-4 is calculated from tests already available — it is a calculation, not an additional blood test.

Investigation	Clinical question it answers	What result changes management?
Repeat LFTs (ALT, AST, ALP, GGT, bilirubin, albumin, total protein)	Has the modifiable cause been removed? Recheck 4–6 weeks after stopping a suspected drug or alcohol, or after a transient illness — alongside, not instead of, the aetiology screen.	Normalised → cause recorded, safety-net and planned recheck (e.g. DILI after stopping drug). Persists despite a negative screen → hepatology with the full screen. Worsening → accelerate urgency.
FBC (full blood count)	Macrocytosis (MCV >100 fL) → alcohol-related or B12/folate deficiency. Thrombocytopenia → portal hypertension (hypersplenism), alcohol bone marrow suppression, or autoimmune hepatitis. Anaemia → coeliac, blood loss, haemolysis.	MCV >100 plus raised GGT plus thrombocytopenia = strong alcohol-related liver disease signal. Pancytopenia in context of cirrhosis → urgent hepatology referral for variceal screening.
Coagulation — PT / INR	Prothrombin time / INR is the most sensitive marker of hepatic synthetic function. Albumin reflects chronic synthetic function; INR reflects acute. INR >1.2 (not on anticoagulants) = significant hepatocellular dysfunction.	INR ≥1.5 plus new encephalopathy after acute liver injury (without established cirrhosis) = acute liver failure — immediate hospital admission. INR 1.2–1.5 (not anticoagulated) → exclude vitamin K deficiency and malabsorption; if hepatic, urgent hepatology referral.
Fasting glucose / HbA1c + lipid profile	Metabolic syndrome is the driver of MASLD. T2DM independently worsens MASLD fibrosis progression. Dyslipidaemia with hypertriglyceridaemia is particularly associated with steatosis.	T2DM or impaired fasting glucose plus raised LFTs plus BMI >25 = MASLD until proven otherwise. FIB-4 score must be calculated. Management becomes multifactorial — metabolic, not just hepatic.
Hepatitis B surface antigen (HBsAg) + hepatitis C antibody (anti-HCV)	Hepatitis B and C are the most common causes of chronic hepatocellular injury worldwide and are significantly underdiagnosed in the UK. Hepatitis B surface antigen and hepatitis C antibody are part of the standard liver aetiology screen for raised ALT of unknown cause (BSG/BASL guideline, Newsome et al., Gut 2018).	HBsAg positive → refer hepatology, antiviral therapy assessment, HCC surveillance, partner notification. Anti-HCV positive → HCV RNA PCR → direct-acting antiviral therapy (cure rate >95%).
Abdominal ultrasound	First-line imaging and part of the standard liver aetiology screen at the first visit, whatever the level or duration (BSG 2018). Identifies hepatic steatosis (echogenic liver), hepatomegaly, cirrhosis morphology, splenomegaly, biliary dilatation, gallstones, focal liver lesions, ascites.	Biliary dilatation → MRCP urgently. Focal liver lesion in high-risk patient → HCC protocol (AFP plus hepatology referral plus CT/MRI). Steatosis confirmed with no biliary pathology → MASLD pathway.
FIB-4 score (calculated: age × AST / [platelets × √ALT])	First-line non-invasive fibrosis risk stratification in primary care in the BSG/BASL 2018 abnormal liver blood tests guideline (NICE NG49 itself uses the ELF test, advanced fibrosis if ≥10.51). Low risk FIB-4 <1.3 — GP manage. Indeterminate 1.3–2.67 — ELF test. High risk >2.67 — hepatology referral (cut-offs 1.3/2.67 as in EASL–EASD–EASO 2024, international; BSG/BASL 2018 uses >3.25 for high risk). Eliminates unnecessary referrals and identifies patients who need them.	FIB-4 <1.3 → manage in primary care, reassess every 2–3 years per local pathway (NG49: ELF every 3 years). FIB-4 1.3–2.67 → ELF or FibroScan. FIB-4 >2.67 → hepatology referral for specialist staging (threshold per local pathway).
Autoimmune liver screen (ANA, ASMA, AMA, anti-LKM1, immunoglobulins)	ANA plus ASMA (anti-smooth muscle antibody) elevated in autoimmune hepatitis (AIH). AMA (anti-mitochondrial antibody) is >95% specific for primary biliary cholangitis (PBC) — the M2 subtype. IgG raised in AIH; IgM raised in PBC.	AMA positive plus elevated ALP plus itching = PBC — refer hepatology for ursodeoxycholic acid initiation. ANA/ASMA positive plus raised IgG plus hepatocellular pattern = AIH — urgent referral as corticosteroid therapy may be needed acutely.
Serum ferritin + transferrin saturation	Screening for haemochromatosis (iron overload) and acute-phase response. Ferritin is also raised in inflammation, alcohol use, metabolic syndrome, and malignancy (confounders). Transferrin saturation >45% is more specific for haemochromatosis than ferritin alone.	Transferrin saturation >45% → HFE gene testing (C282Y homozygosity = hereditary haemochromatosis). Venesection programme prevents cirrhosis, diabetes, and cardiomyopathy if started before end-organ damage.
Serum caeruloplasmin (plus urine copper if positive)	Screening for Wilson's disease in patients under 40 years with unexplained liver disease. Caeruloplasmin <0.2 g/L is strongly suggestive. 24-hour urine copper >0.6 μmol/day confirms diagnosis alongside clinical features.	Low caeruloplasmin in a young patient → urgent hepatology referral. Wilson's is treatable (D-penicillamine, trientine, zinc) and untreated can cause acute liver failure and death.

🎓 SCA Checkpoint — Step 4TasksRelating to OthersGlobal Skills

Key phrases that score

"I would like to send a full set of liver blood tests and arrange a liver scan now, rather than just repeating the test and waiting — that way we find the cause and check for any scarring."

"I would also like to add some additional blood tests to look for the common causes — including viral hepatitis tests and iron levels."

"We can calculate a score from your existing blood tests called the FIB-4 — it gives us a reliable way to tell whether there is any significant scarring of the liver."

Deductions (examiner flags)

Repeating LFTs and waiting instead of sending the liver screen, USS and FIB-4
Not offering viral hepatitis serology to any patient with raised ALT
Failing to calculate or mention FIB-4 in a patient with MASLD or ARLD risk
Not explaining why each investigation is being ordered — comes across as ordering a panel rather than clinical reasoning

🔴 Red — failing

Orders no investigations or inappropriate investigations without clinical rationale. Fails to stage the investigation approach.

🟠 Amber — borderline

Orders some tests but not the full liver screen (hepatitis serology, iron studies, autoantibodies, USS). FIB-4 not mentioned.

🟢 Green — passing

Full liver screen with USS sent in one go, plus pattern-specific tests. FIB-4 mentioned. Hepatitis B and C serology offered. Each investigation linked to a clinical question. Plan explained to patient.

Step 5

Reaching a Diagnosis & DDx — Explained in Plain Language

▲collapse

Most patients with mildly abnormal LFTs feel completely well — explaining why tests that "do not match how they feel" matter is the central communication challenge. The diagnosis must be shared in plain English, framed around the patient's own concerns, and accompanied by a clear explanation of what will happen if left untreated. The differential must distinguish primary care-manageable from hospital-referral diagnoses.

🗣️ Explaining the Diagnosis in Plain Language — say something like this

"Your liver is one of your body's most important organs — it processes everything you eat and drink, makes proteins that help your blood clot, and filters toxins out of your system. Think of it like a large processing factory. Your blood tests suggest the factory is under some strain — not broken, but working harder than it should be. The tests show this by measuring enzymes that leak out of liver cells when they are stressed. The important thing is that these tests can be abnormal for months or years before any symptoms appear, which is actually good news — it means we have caught this at a stage where we can still do something about it and prevent it from getting worse."

💬 Addressing the patient's own explanation — why it may not be the full picture

"I feel completely fine — surely if something was wrong I would know about it?"
"That is actually one of the trickiest things about liver problems — the liver is sometimes called the 'silent organ' because it does not cause pain until it has been under strain for a long time. By the time people feel symptoms, the damage can already be significant. The fact that we have found this early, when you feel well, means we have a real opportunity to prevent it from getting to that point."

"I only have a couple of drinks — my liver must be fine, so it must be something else."
"I hear you, and alcohol is not the only cause — there are lots of reasons liver tests can be abnormal, including the medication you are taking and your weight and blood sugar. But even moderate alcohol can affect the liver tests if other risk factors are also present, so I would like us to look at the whole picture together rather than focus on any one thing."

A — Diagnosable and Manageable in Primary Care

GP can diagnose and manage

MASLD (Metabolic-Associated Steatotic Liver Disease) — fatty liver due to metabolic syndrome. Most common cause in UK. FIB-4 low → manage in primary care with lifestyle intervention.

Alcohol-related liver disease (low fibrosis risk) — FIB-4 <1.3 plus history of hazardous drinking. Brief intervention plus abstinence plus 6-week repeat LFTs.

Drug-induced liver injury (DILI) — causal drug identified, stopped, and LFTs improving. RUCAM score documents causality.

Isolated raised GGT — alcohol, enzyme inducers, or obesity. No other abnormality. Monitor and address cause.

Isolated raised ALP (bone origin) — GGT normal → bone not liver. Paget's disease, rapid bone growth, pregnancy. No hepatic investigation needed.

B — Suspected — Refer to Hepatology

Refer for confirmation

Autoimmune Hepatitis (AIH)

Women predominantly; any age; raised IgG; ANA/ASMA positive; hepatocellular pattern. Can be rapidly progressive — urgent hepatology. Responds to prednisolone plus azathioprine.

Primary Biliary Cholangitis (PBC)

Women aged 40–60; AMA positive (>95%); raised ALP plus GGT; fatigue and pruritus. Diagnose with AMA plus USS; refer for ursodeoxycholic acid (UDCA).

Hereditary Haemochromatosis

Northern European men; transferrin saturation >45%; HFE C282Y. Diagnose in primary care; refer hepatology if ferritin ≥1000 or fibrosis markers raised (fibrosis usually by elastography; liver biopsy not routine).

MASLD with Advanced Fibrosis (FIB-4 >2.67)

FIB-4 >2.67 or ELF elevated → fibroscan plus possible biopsy. Hepatology co-management. Semaglutide for MASH fibrosis is still under technology appraisal (ID6458) — not yet routinely recommended.

Chronic Viral Hepatitis B or C

HBsAg positive or anti-HCV positive → virological assessment plus antiviral therapy planning. HCC surveillance programme. Partner notification.

C — Emergency — Act Now

Diagnose & act

Acute Liver Failure

INR >1.5 plus encephalopathy plus jaundice = ALF regardless of cause. King's College Criteria determine transplant listing. 999 immediately. Causes: paracetamol OD, acute viral hepatitis (A, B, E), acute AIH, Budd-Chiari, acute Wilson's.

Ascending Cholangitis

Charcot's triad: RUQ pain plus fever plus jaundice. Gram-negative sepsis. Requires IV antibiotics plus urgent ERCP within 24–48 hours. Reynolds' pentad (adding shock and confusion) = severity marker.

Hepatocellular Carcinoma / Biliary Malignancy

Raised ALP plus weight loss plus abdominal mass or raised AFP in cirrhotic patient. Suspected cancer pathway referral; urgent CT/USS. Cholangiocarcinoma: painless jaundice plus weight loss plus biliary dilatation on USS.

Variceal Bleeding

Haematemesis or melaena in known or suspected cirrhosis. Mortality 15–20% per bleed. 999 immediately. Terlipressin plus OGD plus banding.

📊 LFT Pattern Recognition — Hepatocellular vs Cholestatic vs Mixed

Pattern	ALT/AST	ALP	GGT	Bilirubin	Likely aetiology	Priority
Hepatocellular	>3× ULN (dominant)	Normal or mildly raised	Raised (any)	Variable	Viral hepatitis, DILI, MASLD, ARLD, AIH, ischaemic	2nd-line workup
Cholestatic	Normal or mildly raised	≥3× ULN (dominant)	Raised (>2× ULN)	Raised	Gallstones, PBC, PSC, biliary stricture, pancreatic malignancy, drugs	USS urgently
Mixed	Raised	Raised	Raised	Variable	Drug-induced (many drugs), infiltrative disease, PSC, ARLD	Full workup
Isolated raised GGT	Normal	Normal	Raised	Normal	Alcohol, enzyme inducers, fatty liver, obesity	GP manage
Isolated raised ALP	Normal	Raised	Normal	Normal	Bone origin: Paget's, bony metastases, puberty, pregnancy	Check GGT / bone profile
AST:ALT >2:1	Raised (AST>ALT)	Variable	Raised	Variable	Supports alcohol-related liver disease (ARLD) — not diagnostic alone	AUDIT-C + FIB-4

🎓 SCA Checkpoint — Step 5TasksRelating to OthersGlobal Skills

Key phrases that score

"I want to explain what these results mean — the liver is releasing some enzymes into the blood, which tells us it is under some stress."

"The most likely explanation, given everything you have told me, is that the fatty liver associated with your weight and blood sugar is causing this — it is called fatty liver disease."

"I know the word 'liver disease' sounds scary — I want to reassure you that at this stage, we are looking at something we can very likely reverse with lifestyle changes."

Deductions (examiner flags)

Not naming a working diagnosis — leaving the patient without a clinical hypothesis
Using technical language (transaminases, cholestatic) without plain-English translation
Not addressing the patient's fear of cancer or cirrhosis if it has been expressed or signalled
Not distinguishing hepatocellular from cholestatic pattern in the explanation

🔴 Red — failing

No diagnosis shared. Technical language only. Does not address patient's concern about cancer or serious disease.

🟠 Amber — borderline

Diagnosis named but not explained in plain language. Patient concern not explicitly addressed. No analogy or patient-facing framing used.

🟢 Green — passing

Diagnosis shared in plain English. Analogy used. Most likely cause named with reference to patient's own history. Cancer or cirrhosis fear explicitly named and addressed. Patient asked if they understand.

Step 6

If Referral Is Needed — What the GP Does Before & During

▲collapse

Knowing when to refer, what to do before referral, and what not to do are the three pillars of GP excellence in liver disease. Most abnormal LFTs can be managed entirely in primary care. Referral is indicated when: (1) the aetiology cannot be determined after second-line workup, (2) fibrosis markers suggest significant or advanced disease (FIB-4 >2.67), (3) an autoimmune, hereditary, or viral cause is confirmed needing specialist therapy, or (4) emergency decompensation. The GP who refers without FIB-4 and USS is sending the hepatologist a referral without the minimum clinical information they need.

Condition / Scenario	Urgency	What GP does before referral	What GP must NOT do
Acute liver failure (encephalopathy + INR >1.5 + jaundice)	999 immediately	Call 999. Brief GP letter with medication list and timeline. If paracetamol overdose is suspected — emergency transfer now; NAC is time-critical and given in hospital without waiting for a level in staggered overdose.	Do not delay admission to complete investigations. Do not administer sedatives. Do not wait for LFT results before referring.
Hepatocellular carcinoma suspected (raised AFP + focal liver lesion + cirrhosis)	Urgent hepatology via local HCC pathway	Complete the urgent HCC-pathway referral with AFP level, USS report, hepatitis B/C serology, and FIB-4 score. Arrange AFP baseline. Ensure patient is pre-counselled that further investigation is needed.	Do not biopsy focal liver lesions in primary care. Do not reassure that a liver lesion is "probably benign" without specialist review.
Advanced fibrosis or cirrhosis (FIB-4 >2.67 or ELF elevated)	2–4 weeks	Arrange fibroscan if available locally prior to referral. Calculate FIB-4. Order USS abdomen plus AFP. Ensure hepatitis B/C serology done. Start appropriate alcohol harm reduction if ARLD. Stop hepatotoxic drugs.	Do not reassure a patient with FIB-4 >2.67 that their liver is "fine." Do not defer referral because patient is reluctant — document the offer. Do not start UDCA without confirming PBC diagnosis.
Autoimmune hepatitis (suspected — ANA/ASMA positive + raised IgG)	2–4 weeks (urgent if ALT >5× ULN)	Complete autoimmune screen (ANA, ASMA, AMA, anti-LKM1, IgG, IgA, IgM). Arrange USS. Stop any hepatotoxic medications. Do NOT start corticosteroids without histological confirmation.	Do not start immunosuppression in primary care. Corticosteroids without biopsy may cause harm if the diagnosis is incorrect (e.g. viral hepatitis).
Primary biliary cholangitis (AMA positive + cholestatic pattern)	4–6 weeks	Confirm AMA M2 positivity, raised IgM, and cholestatic LFT pattern. USS to exclude biliary obstruction. Cholestyramine for pruritus if severe while awaiting referral. Document symptom severity.	Do not start ursodeoxycholic acid (UDCA) without confirmed diagnosis — UDCA requires monitoring in specialist context first.
Hereditary haemochromatosis (C282Y homozygous confirmed)	Routine	Arrange serum ferritin, transferrin saturation, and HFE gene test. Once C282Y homozygosity confirmed → routine hepatology referral. Advise patient to avoid iron supplements. Recommend family screening for first-degree relatives.	Do not start venesection without specialist assessment of ferritin targets and cardiac/hepatic status. Do not miss first-degree relative screening.
LFTs raised >6 months, aetiology unclear after full second-line workup	Routine hepatology referral	Compile complete investigation results: LFT trend (dated), FIB-4 calculation, USS report, autoimmune screen, viral serology, iron studies, FBC, coagulation, HbA1c, lipids, alcohol AUDIT score. Refer with complete data to prevent duplication.	Do not refer without completing basic second-line workup first — incomplete referrals cause delays and duplication. Do not discharge without a safety-net plan if the patient is not referred.

🎓 SCA Checkpoint — Step 6TasksRelating to OthersGlobal Skills

Key phrases that score

"Based on these results, I do not think you need to see a hospital specialist today — but I do want to complete the investigation first and then review where we are."

"If the fibrosis score comes back as higher risk, I will refer you to a liver specialist who can do a more detailed scan and advise on treatment."

"I will make sure the referral letter includes all your blood results and the scan so the specialist has everything they need."

Deductions (examiner flags)

Referring without completing minimum workup (FIB-4, USS, viral serology)
Failing to explain to the patient why referral is or is not needed
Starting UDCA or corticosteroids without specialist confirmation of diagnosis
Missing the suspected cancer pathway for cholestatic pattern with constitutional symptoms

🔴 Red — failing

Inappropriate urgency level. Refers without minimum workup. Starts specialist treatment without diagnosis confirmed.

🟠 Amber — borderline

Correct referral decision but urgency level wrong. Incomplete pre-referral workup. Patient not told what referral is for.

🟢 Green — passing

Correct urgency. Pre-referral investigations complete. Clear explanation to patient about what referral involves and what to expect. Suspected cancer pathway correctly identified where indicated.

Step 7

Management — Expectation · Goals · Lifestyle · Prescribing · Drug Cards · Psychosocial · Follow-Up · Safety-Netting

▲collapse

Management of abnormal LFTs in primary care is fundamentally about the underlying aetiology — there is no single drug for "abnormal LFTs." Management depends on whether the cause is metabolic (MASLD — lifestyle first), alcohol-related (harm reduction and abstinence support), drug-induced (stop the offending drug), viral (antivirals), autoimmune (immunosuppression, specialist-led), or hereditary (specific treatment per condition). The GP's role across all aetiologies is the same: explain the diagnosis clearly, set realistic goals, optimise modifiable risk factors, and ensure the patient is monitored appropriately with a clear escalation plan.

7A — Address the patient's expectation first: validate → explain → negotiate

🤝

Never dismiss the expectation — acknowledge it, share your reasoning, then agree a shared plan

Validate — name their expectation

Most patients attend expecting either definitive reassurance ("it is nothing") or immediate intervention ("I need a scan"). Name what they expected, and acknowledge that their concern is reasonable regardless of the final outcome.

"I completely understand why you would want to know exactly what is going on — an abnormal blood test is worrying, and it makes total sense that you want answers today."

Explain — share your clinical reasoning

Explain why the investigation plan is staged, why you are not ordering everything today, and what the reasoning behind each test is. Patients who understand the plan are more likely to attend follow-up and engage with lifestyle advice.

"The reason I want to do the full set of tests and a scan now, rather than just repeating the blood test, is that how high the numbers are does not tell us how healthy the liver is — so it is better to find the cause and check for scarring straight away."

Negotiate — offer something today

Even if the investigation plan is watchful waiting, always leave the patient with something concrete: a lifestyle target, a repeat blood test date, a written plan, a contact number if symptoms develop. Leaving with nothing is a missed opportunity.

"So here is what we will do today: I will arrange the liver blood tests and a scan, we will recheck the liver tests once the ibuprofen has stopped and review everything in 8 weeks, and in the meantime I would like to go through what you can do now that we know will genuinely help — can we do that together?"

Key principle: The patient with "mildly abnormal liver tests" is at a clinical crossroads — engaged now, they can prevent cirrhosis; dismissed now, they will not return until the disease is symptomatic and advanced. The consultation today is the most important intervention.

7B — Why treatment matters: goals tailored to this patient

Treatment goals — aetiology-specific

Prevent progression to cirrhosis Normalise liver enzymes in 8–12 weeks Reduce fibrosis stage (reversible at F1–F3) Eliminate the causative factor (alcohol, drug, metabolic) Treat comorbid metabolic syndrome comprehensively Achieve cure if viral hepatitis (HCV — >95% cure rate with DAAs) Fibrosis reassessed every 2–3 years if low risk (local pathway) HCC surveillance if confirmed cirrhosis (6-monthly USS ± AFP)

Motivational language — tailored to this patient

"The good news is that liver scarring at an early stage is reversible — the liver is one of the few organs that can repair itself if we remove the cause. Studies show that people who make significant lifestyle changes can reduce their liver enzyme levels by up to 50% in just 12 weeks."

"I am thinking about what you told me — that you want to be there for your children. Managing your liver health now is one of the most important things you can do for that — because without treatment, fatty liver disease can silently progress to a point where it affects your overall health significantly."

7C — Non-medication management: mechanism + evidence + tailored advice

Lifestyle intervention is the primary treatment for both MASLD and ARLD — not an optional add-on. A 5–10% reduction in body weight reduces hepatic steatosis by 40–80%, and a 10% reduction in weight can reverse early MASH. Advice must be specific, measurable, and feasible within the patient's psychosocial context. Generic "eat less and exercise more" is not a treatment plan.

⚖️

Weight Reduction

Target: 5–10% body weight loss over 6–12 months

Mechanism

Visceral adipose tissue drives hepatic steatosis via free fatty acid flux and insulin resistance. Weight loss reduces hepatic fat content, ALT, and fibrosis progression. Even 3–5% weight loss reduces steatosis significantly.

Practical

Mediterranean diet (olive oil, fish, vegetables, whole grains, limited red meat and processed food) has the best evidence base for MASLD (clinical practice). Calorie deficit of 500–750 kcal/day achievable via dietary diary and dietitian referral. Referral to tier 2 or 3 weight management services if BMI >35.

10% weight loss → reversal of MASH in up to 90%

🏃

Physical Activity

150 min moderate aerobic activity per week

Mechanism

Exercise independently reduces hepatic steatosis through AMPK activation and improved insulin sensitivity, even without weight loss. Resistance training additionally reduces visceral adiposity and improves metabolic parameters.

Practical

150 minutes moderate intensity (brisk walking, cycling, swimming) per week OR 75 minutes vigorous. Add 2 sessions resistance training weekly. NHS Couch to 5K app is evidence-based for sedentary patients. Social prescribing to walking groups or leisure centre referral.

Exercise alone reduces ALT by ~25% without weight change

🍷

Alcohol Reduction / Abstinence

Complete abstinence if ARLD; ≤14 units/week if MASLD

Mechanism

Alcohol directly damages hepatocytes via oxidative stress (acetaldehyde), mitochondrial dysfunction, and endotoxin-mediated inflammation. In ARLD, abstinence can normalise LFTs and even reverse early cirrhosis. In MASLD, alcohol worsens steatohepatitis even at moderate intake levels.

Practical

AUDIT-C score first. If hazardous or harmful: brief intervention, leaflets (Drinkaware, Alcohol Change UK). If dependent: refer alcohol liaison ARLD pathway — do NOT advise abrupt cessation (seizure risk). Supported withdrawal with community or inpatient detox. Alcohol care team referral if available.

Abstinence normalises GGT in 4–6 weeks; reverses early cirrhosis in 1–2 years

🩸

Glycaemic and Metabolic Control

HbA1c individualised (usually 48 mmol/mol; 53 on a hypo-causing drug, NICE NG28); BP to NICE NG136 target; LDL-C ≤2.0 mmol/L in secondary prevention (NICE NG238)

Mechanism

Insulin resistance is the central pathophysiological driver of MASLD. Hyperglycaemia drives hepatic gluconeogenesis and de novo lipogenesis, directly worsening steatosis and fibrosis. GLP-1 receptor agonists (semaglutide) have specific hepatoprotective effects beyond glycaemic control.

Practical

Optimise T2DM management (metformin continues — safe in MASLD unless eGFR <30; MR metformin + SGLT-2i is now dual first-line under NICE NG28, Feb 2026; GLP-1 RA a preferred further agent — both have hepatoprotective effects). Blood pressure control with ACEi or ARB if proteinuria present. Statin for CVD risk reduction (safe in liver disease; NICE NG238).

Semaglutide 2.4 mg resolved MASH in 62.9% vs 34.3% on placebo at 72 weeks (ESSENCE, NEJM 2025)

💊

Medication Review

Remove hepatotoxic drugs; review all supplements

Mechanism

DILI accounts for up to 20% of acute liver failure cases. NSAIDs, herbal remedies, and supplements are the most commonly missed causes because patients do not volunteer this information. The RUCAM score quantifies likelihood of drug causation.

Practical

Stop all herbal supplements immediately. NSAIDs: switch to paracetamol (reduce the dose: commonly max 3 g/day with risk factors; some SPCs advise 2 g/day in chronic heavy alcohol use — check the SPC) or topical NSAID. Statins: do not stop without cause — safe in liver disease and provide hepatoprotection. If DILI confirmed: Yellow Card reporting and RUCAM documentation.

DILI resolves in 80% within 8 weeks of stopping the offending drug

💉

Vaccination & Infection Prevention

Hepatitis A + B vaccination if not immune; pneumococcal + influenza annually if cirrhosis

Mechanism

Patients with chronic liver disease have impaired innate immunity — infections are disproportionately severe. Hepatitis A superimposed on chronic liver disease has mortality of up to 70%. Annual influenza vaccination halves hospitalisation risk in cirrhosis.

Practical

Check hepatitis A and B immunity status (anti-HAV IgG, anti-HBs). Vaccinate if non-immune — accelerated Hep B schedule available if urgent. Pneumococcal vaccination in chronic liver disease per the current UKHSA Green Book (PCV20 replaced PPV23 for clinical risk groups). Annual influenza vaccination. Avoid live vaccines if on immunosuppression (AIH).

Hep A superinfection on chronic liver disease: 70% mortality — vaccination is essential

7D — Prescribing guide: what to start, in what order, and why

There is no single pharmacotherapy for "abnormal LFTs" — treatment is aetiology-specific. The prescribing ladder below reflects the most common primary care scenarios. Statins, SGLT-2 inhibitors, and GLP-1 receptor agonists are the drugs most likely to be initiated in primary care for MASLD. Antivirals for hepatitis B and C, ursodeoxycholic acid for PBC, and immunosuppression for AIH are specialist-initiated. Always review the medication list for hepatotoxic drugs before adding new ones.

Step 1 — Lifestyle and Optimise Metabolic Control (all MASLD)

Mediterranean diet + 150 min/week exercise + alcohol reduction + BMI reduction 5–10%

Stop hepatotoxic drugs (NSAIDs, herbal supplements)
Optimise glycaemic control (metformin continues, paired with an SGLT-2i as dual first-line per NICE NG28, Feb 2026; GLP-1 RA a preferred further agent)
Statin for CVD risk reduction — safe in liver disease (NICE NG238; do not stop)
Blood pressure control — ACEi or ARB if microalbuminuria or proteinuria

Repeat LFTs at 8–12 weeks. If no improvement → Step 2.

Step 2 — Drugs with possible liver benefit: for their diabetes/obesity indications only

Weight loss is the mainstay; drug therapy for MASH is specialist-led

Semaglutide 2.4 mg SC weekly — strong MASH-resolution evidence (ESSENCE trial), but used off-label for MASH in the UK; licensed/funded here for obesity/T2DM, not MASH per se
SGLT-2 inhibitors (empagliflozin, dapagliflozin) — hepatic + cardiorenal benefit; a rational choice in coexisting T2DM
Pioglitazone — improves MASH histology (specialist-initiated, off-label); avoid in heart failure, bladder cancer, high fracture risk
Vitamin E (800 IU/day) — NICE NG49: pioglitazone or vitamin E may be considered for advanced fibrosis, with or without diabetes, in secondary or tertiary care only

Hepatology co-management required if FIB-4 >2.67 before initiating MASH-specific therapy.

Step 3 — Aetiology-Specific Treatments (Specialist-Initiated)

Initiated by hepatology / gastroenterology — GP role is monitoring and prescription continuity

Hepatitis C: direct-acting antivirals (sofosbuvir-based regimens) — 8–12 weeks, >95% cure; GP can co-prescribe under shared care
Hepatitis B: tenofovir or entecavir — lifelong antiviral suppression; GP monitors renal function and HBV DNA annually
PBC: ursodeoxycholic acid (UDCA) 13–15 mg/kg/day — initiated by hepatology, GP prescribes on shared care
AIH: prednisolone plus azathioprine — specialist initiated; GP monitors FBC and LFTs monthly
Haemochromatosis: therapeutic venesection — 1 unit blood every 1–2 weeks until ferritin <50 μg/L, then maintenance phlebotomy
Wilson's disease: D-penicillamine or trientine — specialist managed; GP monitors urine copper and FBC

Shared care protocol required before GP prescribes specialist-initiated treatments. Check local formulary.

Step 4 — Acute Decompensation Management (Hospital)

Acute liver failure: N-acetylcysteine IV (paracetamol OD), King's College criteria assessment, ICU, transplant listing consideration.

Variceal bleeding: Terlipressin IV plus OGD plus band ligation. Propranolol for secondary prevention (target HR 55–60 bpm).

Ascites: Low-sodium diet (<90 mmol/day NaCl), spironolactone 100 mg OD (titrate up), furosemide 40 mg OD if needed. Paracentesis if tense ascites. Prophylactic norfloxacin if previous SBP.

Hepatic encephalopathy: Lactulose (titrate to 2–3 soft stools/day), rifaximin 550 mg BD for recurrent episodes, dietary protein not restricted below 1.2 g/kg/day.

Special Prescribing Situations

Statins in liver disease: SAFE and beneficial in MASLD and compensated ARLD. Do NOT stop statins because of mildly raised LFTs (<3× ULN) — the risk of stopping (increased CVD mortality) outweighs the hepatic risk. Persistent unexplained >3× ULN → investigate and withhold pending review; not automatic permanent discontinuation (NICE NG238).

Paracetamol in liver disease: Preferred analgesic; dose by weight, nutrition, alcohol use and severity of hepatic impairment — reduce the dose: commonly maximum 3 g/day with risk factors; some SPCs advise 2 g/day in chronic heavy alcohol use — check the SPC. Avoid duplicate paracetamol-containing products (SPS).

Metformin in liver disease: Continue in MASLD and compensated cirrhosis. Withhold if AKI or severe hepatic impairment (risk of lactic acidosis). Not contraindicated by liver disease alone.

NSAIDs in cirrhosis: Absolutely contraindicated — risk of AKI, GI bleeding (variceal plus NSAID-related), and hepatorenal syndrome. Use paracetamol or opioids if analgesic needed.

7E — Medication options — guideline summary (no patient selection)

Situations this summary covers

Type 2 Diabetes / metabolic syndrome
MASLD with confirmed fibrosis (FIB-4 >1.3)
Established cardiovascular disease
Alcohol-related liver disease (ARLD)
BMI >30 or waist >94 cm men / >80 cm women
Confirmed viral hepatitis (B or C)
Drug-induced liver injury (identified cause)
Autoimmune or hereditary cause confirmed
Cirrhosis with decompensation

Pharmacotherapy guidance for LFTs

Refer to drug cards below for detailed prescribing information.

Guideline summary — each situation is shown with what the guidance says for it, as written. Nothing is selected or worked out for an individual patient. Check doses in the current SPC and local formulary.

7F — Drug reference cards: liver-aetiology pharmacotherapy

GLP-1 Receptor Agonists

Semaglutide (Ozempic / Wegovy), liraglutide

✓ Recommended

T2DM/obesity indicationSema 0.25–2.4 mg SC/wk

✓ Prefer when

MASLD / MASH plus T2DM or obesity (licensed for those indications; MASH benefit is off-label)

BMI >27 with obesity-related comorbidity

Weight reduction goal as well as hepatic — dual benefit

Established CVD with MASLD — cardiorenal protective

✗ Avoid if

Personal or family history of medullary thyroid carcinoma

MEN-2 syndrome

Pancreatitis (personal history — use with caution)

Severe renal impairment eGFR <15 (limited data)

⚠ Side effects

Nausea, vomiting, diarrhoea — dose-dependent, improve over 4–8 weeks

Injection-site reactions

Gallstones — rapid weight loss increases biliary lithogenesis

🔬 Monitor

LFTs at 3 and 6 months after initiation

Weight, HbA1c, eGFR annually

USS abdomen if new RUQ symptoms (gallstones)

💬 Counselling

"This medication will help reduce the fat in your liver and also help with weight loss. It comes as a weekly injection. The most common side effect is nausea — it is usually mild and improves over the first few weeks."

GLP-1 RAs are not yet approved for MASH on the NHS (semaglutide technology appraisal ID6458 in progress) — a strong pass candidate mentions their liver benefit and links it to the patient's T2DM and BMI rather than treating it as a diabetes drug alone.

SGLT-2 Inhibitors

Empagliflozin (Jardiance), dapagliflozin (Forxiga)

✓ Recommended

MASLD + T2DMEmpa 10–25 mg OD

✓ Prefer when

MASLD plus T2DM — hepatoprotective and cardiorenal benefit

Heart failure with MASLD — empagliflozin reduces hepatic congestion

CKD (eGFR >20) with MASLD — slows renal decline and reduces LFTs

When weight loss is also a goal (average 2–3 kg loss)

✗ Avoid if

Type 1 diabetes (risk of DKA)

eGFR <20 (no glucose-lowering benefit for glycaemic indication)

Recurrent UTIs or genital thrush

Ketogenic diet or prolonged fasting (DKA risk)

⚠ Side effects

Genital mycotic infections (especially women) — advise hygiene

UTIs — drink adequate fluid

Euglycaemic DKA — rare but serious; sick-day rules important

🔬 Monitor

eGFR and electrolytes at 4 weeks after initiation then annually

LFTs at 3 months (expect modest reduction in ALT)

Blood pressure (modest hypotensive effect)

💬 Counselling

"This tablet helps your kidneys remove excess sugar via the urine — it also benefits your liver and heart. Make sure to stay well hydrated. If you become unwell and cannot eat, hold the tablet and contact us — we will give you sick-day rules to keep you safe."

SGLT-2i are NOT just diabetes drugs — their hepatoprotective, cardiorenal, and volume-reducing effects make them a natural fit in MASLD plus T2DM — and NICE NG28 (Feb 2026) now makes them dual first-line with metformin for most adults with T2DM. Naming this mechanism in an SCA scores Tasks domain marks.

Ursodeoxycholic Acid (UDCA)

Ursofalk, Destolit — specialist initiated

✓ Recommended

PBC 1st line13–15 mg/kg/day in 2–3 divided doses

✓ Prefer when

Primary biliary cholangitis (PBC) — AMA positive, cholestatic LFT pattern

Confirmed diagnosis by hepatology — not initiated in primary care

Primary sclerosing cholangitis (PSC) — less clear benefit but used

✗ Avoid if

Acute cholecystitis or biliary obstruction — cholangitis risk

Do NOT initiate without confirmed PBC diagnosis

Inflammatory bowel disease — limited data on safety in active colitis

⚠ Side effects

Generally well tolerated

Diarrhoea at higher doses — take with food

Worsening pruritus in first weeks (bile acid flux effect)

🔬 Monitor

LFTs at 3, 6, 12 months — at 12 months, ALP >1.67× ULN or raised bilirubin = inadequate response (BSG 2018)

If no response at 12 months → obeticholic acid (second line, specialist)

Annual assessment of fibrosis stage

💬 Counselling

"This medication works by replacing a toxic bile acid in your liver with a gentler one, reducing the damage to your bile ducts. It is a long-term treatment and needs regular monitoring — we will check your blood tests every few months to make sure it is working."

The SCA examiner will note if you initiate UDCA in primary care without diagnosis confirmed — this is a deduction. The correct phrase is: "Once the specialist confirms PBC, they will start UDCA and we will monitor you in primary care from then on."

Direct-Acting Antivirals (DAAs)

Sofosbuvir/velpatasvir (Epclusa), glecaprevir/pibrentasvir (Maviret) — Hep C

✓ Recommended

Hep C cure8–12 weeks course

✓ Prefer when

Hepatitis C confirmed (anti-HCV positive plus HCV RNA detectable) — all genotypes

All patients with chronic HCV regardless of fibrosis stage — curative, not suppressive

HCV plus cirrhosis — cure significantly reduces HCC risk (50% reduction)

✗ Avoid if

Decompensated cirrhosis with sofosbuvir/NS5A regimens — specialist only

Significant drug interactions (rifampicin, carbamazepine — check SPC)

Hepatitis B coinfection — risk of HBV reactivation on DAA therapy

⚠ Side effects

Generally very well tolerated — fatigue and headache most common

Drug interactions — check SPC/MIMS before co-prescribing

HBV reactivation in HBV/HCV coinfection

🔬 Monitor

HCV RNA at end of treatment plus 12 weeks post-treatment (SVR12 = cure)

LFTs at 12 weeks post-treatment — should normalise if SVR achieved

Continue HCC surveillance if cirrhosis present even after cure (risk persists)

💬 Counselling

"The good news is that hepatitis C is now curable with a tablet course. Over 95% of people with hepatitis C are cured with an 8–12 week course of these tablets. We will check a blood test 12 weeks after finishing to confirm the virus has gone."

HCV cure with DAAs is one of modern medicine's great success stories — >95% cure rate with less than 12 weeks of oral therapy. Naming this clearly in the SCA scores a Tasks domain point and demonstrates up-to-date clinical knowledge.

Pioglitazone

Actos — thiazolidinedione (TZD)

✓ Recommended

Specialist only (NG49)30–45 mg OD

✓ Prefer when

MASH (metabolic-associated steatohepatitis) histologically confirmed

MASLD plus T2DM — improves insulin sensitivity and hepatic steatosis

Advanced fibrosis with or without diabetes — off-label; secondary/tertiary care only (NICE NG49)

✗ Avoid if

Heart failure (any grade) — fluid retention worsens cardiac failure

Bladder cancer or history of — associated with increased risk

Osteoporosis or high fracture risk — increases fracture risk in women

Oedema or fluid retention already present

⚠ Side effects

Weight gain (average 2–4 kg) — counterintuitive in MASLD context; explain to patient

Peripheral oedema

Increased bone fracture risk (especially postmenopausal women)

🔬 Monitor

LFTs at 3 and 6 months — expect ALT reduction of 30–50%

Monitor for oedema and weight gain clinically

Annual DEXA scan if on long-term therapy in women at fracture risk

💬 Counselling

"This medication improves the way your body handles insulin, which reduces the fat and inflammation in your liver. You may notice some mild fluid retention and weight gain — this is known and expected. Please tell us if you notice your ankles swelling significantly."

Pioglitazone is contraindicated in heart failure — the SCA examiner will test this. If the stem includes heart failure, naming the contraindication scores marks. Do not confuse pioglitazone's benefit (MASH) with its risk (cardiac fluid retention).

Spironolactone

Aldactone — for ascites management in cirrhosis

✓ Recommended

Cirrhosis ascites100 mg OD (titrate to max 400 mg)

✓ Prefer when

Cirrhosis with ascites — first-line diuretic (sodium restriction plus spironolactone)

Portal hypertension plus hyperaldosteronism (mechanism of ascites)

Furosemide added if spironolactone alone insufficient (ratio 100:40)

✗ Avoid if

Hyperkalaemia (K+ >5.5 mmol/L) — check before starting

AKI or creatinine >200 μmol/L (consult hepatology)

Renal impairment — monitor closely; reduce dose if creatinine rising

⚠ Side effects

Hyperkalaemia — monitor closely, especially if concurrent ACEi/ARB/K-sparing diuretics

Gynaecomastia (anti-androgen effect) — consider eplerenone if troublesome

Hyponatraemia — restrict fluid if Na+ <125 mmol/L

🔬 Monitor

U&E plus creatinine at 1 week, 4 weeks, then monthly for first 3 months

Weight daily (home) — aim <0.5 kg/day weight loss if no peripheral oedema

Abdominal girth measurement at each review

💬 Counselling

"This water tablet specifically targets the type of fluid build-up that happens with liver disease. Please weigh yourself every morning at home and let us know if you gain more than 2 kg over 2 days — it may mean we need to adjust the dose."

Spironolactone in cirrhosis must be paired with sodium restriction (<90 mmol/day sodium ≈ 2 g sodium, about 5 g salt) — advising both is a Tasks domain marker. Furosemide is always added at a ratio of 40 mg for every 100 mg spironolactone (never furosemide alone in cirrhotic ascites).

7G — Psychosocial impact of the diagnosis: driving, work, relationships & daily life

🤝

Living with a liver diagnosis — what the patient needs to know beyond the clinical facts

A liver diagnosis carries disproportionate social stigma — particularly when it is alcohol-related. Patients may conceal the diagnosis from family, employers, and insurers, leading to delayed treatment and poor adherence. Healthcare professionals must proactively address the real-life consequences of the diagnosis, as patients are unlikely to volunteer these concerns without prompting. Shame is one of the most powerful barriers to engagement with alcohol-related liver disease treatment.

🚘

Driving

Stable MASLD or chronic viral hepatitis without decompensation: no driving restriction, no DVLA notification required.

Cirrhosis with encephalopathy (even single episode): must stop driving and notify DVLA — encephalopathy impairs cognitive function required for safe driving.

Hepatic encephalopathy is a notifiable condition to DVLA (Group 1 and Group 2 licences). HGV/PCV licence holders with cirrhosis face more stringent DVLA criteria — refer to DVLA medical unit.

"I do need to mention driving — as long as you are feeling well and there is no confusion from the liver, you are fine to drive. But I will let you know if that ever changes."

💼

Work and Employment

MASLD and compensated chronic liver disease: no occupational restriction in most jobs. Fatigue is common and may affect productivity — acknowledge it clinically.

Certain occupations require DVLA or occupational health notification: pilots, HGV drivers, merchant seafarers, armed forces, and safety-critical roles. Hepatic encephalopathy precludes these roles.

Alcohol-related liver disease may warrant referral to occupational health if there is a workplace drinking culture or if the patient needs time off for treatment.

"Your liver condition should not affect your ability to work for now — but if you need a sick note or a letter for occupational health, please let us know."

💑

Relationships and Disclosure

Hepatitis B and C are transmissible — partner notification is a clinical and public health duty. Sexual partners and household contacts require testing and vaccination (Hep B).

The diagnosis of liver disease — particularly if alcohol-related — carries significant relationship impact. Partners may feel deceived by concealed drinking; the diagnosis can be a crisis point or a catalyst for change.

Offer to involve partners (with consent) in the discussion of the diagnosis and management plan — this significantly improves ARLD treatment engagement.

"Is there someone close to you who you would like to be involved in understanding the diagnosis? Sometimes it helps to have a second pair of ears — and for hepatitis, we do need to check your family members as well."

🏋

Physical Activity and Daily Life

Exercise is beneficial and encouraged in MASLD, ARLD (compensated), and chronic viral hepatitis. No restriction on activity in compensated liver disease.

Contact sports should be avoided in patients with known portal hypertension (splenomegaly) — risk of splenic rupture from blunt abdominal trauma is increased.

Fatigue is a common and underrecognised symptom of chronic liver disease (especially PBC) — validate it, as patients often feel dismissed when they describe fatigue with normal-looking tests.

"The fatigue you are feeling is real and is a known part of liver disease — it is not 'just stress.' We can look at ways to manage it and refer you if it is significantly affecting your quality of life."

🍺

Alcohol and Social Life

For ARLD patients: complete abstinence is the goal, not harm reduction. Even moderate alcohol in established liver disease significantly worsens fibrosis. This must be communicated clearly but without shame.

For MASLD without ARLD: keep within the lower-risk limit of 14 units/week (not a safe limit) — alcohol worsens steatohepatitis even at moderate intake levels due to additive hepatotoxic effects.

Social life disruption from abstinence is a significant barrier — refer to alcohol liaison, ARLD peer support groups, and Alcoholics Anonymous if the patient is willing.

"I know asking you to stop drinking completely is a big ask — and I want to help you work out how to do that in a way that fits your life. Can we talk about what support might help?"

🛡️

Insurance and Legal Implications

Life insurance and critical illness policies: liver disease (especially cirrhosis) may affect premium costs or exclusions. Patients should seek financial advice but are not required to retrospectively disclose to existing policies — only new policies require declaration.

Travel insurance: declare liver disease, particularly if cirrhosis or on specialist treatment. Failure to declare may invalidate cover.

Alcohol-related liver disease and employment: the Equality Act 2010 does not protect alcohol dependence itself, but associated mental health conditions may require reasonable adjustment.

"I would encourage you to check with your travel and life insurers about your liver condition — it is better to declare it and know where you stand than to find out later there is a problem with cover."

7H — Follow-up schedule

8 weeks — Review the liver screen, USS and FIB-4, plus repeat LFTs

Review repeat LFTs trend (improving, static, or worsening). Review hepatitis B/C serology results. Calculate FIB-4 score from baseline bloods. Discuss lifestyle change progress. If LFTs normalised and aetiology identified — monitor 6-monthly for 12 months then annually.

First critical review pointFIB-4 calculation due

3 months — Liver USS results plus fibrosis stratification plus medication review

Review USS results (steatosis, hepatomegaly, biliary pathology, focal lesions). Review autoimmune screen results if sent. If FIB-4 high risk (>2.67, per local pathway) → hepatology referral. Review medication adherence and side effects. Alcohol AUDIT-C re-scoring if ARLD. Body weight, BMI, and waist circumference re-measured.

Referral decision pointUSS review

6 months — Glycaemic and metabolic reassessment plus lifestyle progress review

HbA1c, lipid profile, blood pressure re-measured. LFT repeat if previously abnormal at 3 months. If LFTs improving with lifestyle intervention: continue and reinforce. If not improving → intensify weight management; GLP-1 RA or SGLT-2i only for their diabetes/obesity indications; pioglitazone or vitamin E only in secondary care (NG49). ELF test if FIB-4 was in indeterminate range (1.3–2.67).

Metabolic reassessmentELF test if needed

12 months — Annual liver disease review (GP chronic disease register)

Metabolic and CV review; LFTs and FBC as clinically indicated. Repeat fibrosis assessment every 2–3 years if low risk (NG49: ELF every 3 years) — no routine serial USS for uncomplicated steatosis. Hepatitis B vaccination if non-immune. Alcohol AUDIT-C annual re-scoring. HCC surveillance (6-monthly USS ± AFP) if confirmed cirrhosis — added to chronic disease register. Medication review (hepatotoxic drugs).

HCC surveillance if cirrhosisAnnual chronic disease review

Ongoing — Specialist-shared care model if advanced disease

If referred to hepatology: GP continues primary care management (metabolic risk factors, medications, vaccinations, monitoring) under shared care protocol. Hepatology manages: fibroscan repeat (2-yearly), HCC surveillance, antiviral therapy, variceal screening OGD. GP escalates immediately for any decompensation (jaundice, ascites, encephalopathy, bleeding).

Escalate immediately if decompensationShared care ongoing

7I — Monitoring: the LFT-FBC-Coag-Metabolic panel plus fibrosis targets

Memory rule

In chronic liver disease: LFTs plus FBC plus Coagulation plus U&E = every 6–12 months. Fibrosis reassessed every 2–3 years if low risk; no routine serial USS for uncomplicated steatosis. If cirrhosis confirmed: HCC surveillance = 6-monthly USS ± AFP, OGD for varices every 1–3 years. Any decompensation → same-day or emergency assessment. Stop monitoring lists = patient falls through the net — add to the chronic disease register.

Parameter	Test	Timing	Action threshold
Liver enzymes	ALT, AST, ALP, GGT, bilirubin, albumin	4–6 weeks after any change, then 6–12 monthly once stable	Rising or >3× ULN persisting → escalate investigation or referral
Synthetic function	INR / PT plus albumin	6-monthly if liver disease confirmed	INR >1.2 (not anticoagulated) or albumin <35 g/L → consider non-hepatic causes (vitamin K, nutrition, inflammation, renal); if hepatic, urgent hepatology referral
Full blood count	FBC — platelets, MCV, Hb	6–12 monthly	Platelets ≤150 × 10⁹/L in suspected advanced liver disease = possible portal hypertension → hepatology referral; variceal screening (OGD) if platelets ≤150 or liver stiffness ≥20 kPa (Baveno VII)
Fibrosis score	FIB-4 (calculated) ± ELF test	Every 2–3 years if low risk (or if metabolic risk changes)	FIB-4 >2.67 → hepatology referral. FIB-4 1.3–2.67 → ELF test. FIB-4 <1.3 → low risk, manage in primary care
Metabolic panel	HbA1c, fasting lipids, BP, weight, waist	6–12 monthly (MASLD)	HbA1c >53 → diabetes management intensification. BMI — 5% reduction target per year if overweight
HCC surveillance	USS abdomen ± AFP	6-monthly if cirrhosis (any cause)	New focal lesion on USS or rising AFP → urgent hepatology/radiology review via the local HCC pathway

Patient group	LFT target	Fibrosis goal
MASLD — low fibrosis risk (FIB-4 <1.3)	ALT <45 U/L, AST <40 U/L, ALP normal	Maintain FIB-4 <1.3 on 2–3-yearly reassessment. No progression to F3/F4.
MASLD plus T2DM — intermediate risk	ALT normalisation plus HbA1c <53 mmol/mol	ELF score <9.8. Hepatology co-management if FIB-4 1.3–2.67.
ARLD — abstinent	GGT normalises 4–6 weeks. ALT normalises 8–12 weeks if early disease.	FIB-4 improvement at 6 months of abstinence is expected in early disease.
Hepatitis C — on DAA treatment	ALT normalisation expected by 4 weeks into treatment	SVR12 (undetectable HCV RNA 12 weeks post-treatment) = cure. FIB-4 improves post-cure over 1–2 years.
PBC — on UDCA	At 12 months: ALP ≤1.67× ULN with normal bilirubin = adequate response (BSG/UK-PBC 2018)	Paris criteria (ALP ≤3× ULN, AST ≤2× ULN, bilirubin ≤17) = adequate UDCA response.
Confirmed cirrhosis	Albumin >35 g/L, bilirubin <50 μmol/L, INR <1.5 = compensated	HCC surveillance 6-monthly. Varices: OGD every 1–3 years. Decompensation markers monitored at every review.

7J — Safety-netting: exact phrases + medico-legal rationale

⚠ Three scenario-specific phrases — use these verbatim

Why safety-netting matters beyond clinical care

Documents that the GP identified potential red flags and communicated them clearly — medicolegal protection

Reduces medicolegal risk if the patient delays seeking help for a decompensation event after an adequate safety-net was given

Satisfies CQC requirements for patient safety systems — all safety-netting should be documented in the consultation record

Improves clinical outcomes — patients who are told exactly what to look for seek help earlier and have better outcomes from decompensation

Empowers the patient — giving them a clear action plan reduces anxiety from ambiguity and improves trust in the therapeutic relationship

Specific symptoms (jaundice, confusion, haematemesis) are more actionable than generic advice — specificity is both clinically and legally superior

8 weeks — Review the liver screen, USS and repeat LFTs. Phone or face-to-face depending on result severity.

Immediately — If any red flag symptoms develop: jaundice, confusion, haematemesis, rapid abdominal swelling → A&E not the waiting room.

Ongoing — Annual review on chronic disease register if persistent liver disease. HCC surveillance if cirrhosis confirmed (6-monthly USS ± AFP).

🎓 SCA Checkpoint — Step 7 (Final)TasksRelating to OthersGlobal Skills

Closing the consultation

"Let me summarise what we have agreed today — does that all make sense, or is there anything you would like to go over?"

"I want to make sure you leave knowing what to do if things change — so the most important warning signs are yellowing of the skin, confusion, or vomiting blood — call 999 for any of those."

"We will send the blood tests off today and book you in for 8 weeks — but please do not wait if you are worried about anything before then."

"Is there anything else on your mind that we have not covered today?"

"I know this has been a lot to take in — is there someone at home you can talk through this with?"

Deductions — closing

Not summarising the plan before closing — patient leaves unclear what the next steps are
Not giving specific safety-net symptoms — "if you feel worse, come back" is insufficient
Not asking a closing question ("anything else?") — may miss the patient's remaining concern
Not addressing alcohol reduction specifically and sensitively if ARLD suspected
Giving an overly optimistic prognosis without acknowledging the need to investigate further
Prescribing new medication (e.g. UDCA, pioglitazone) without specialist confirmation of diagnosis

Tasks domain — full criteria

Named working diagnosis in plain language with cause clearly linked to patient's own history
Investigation plan: full liver screen (hepatitis serology, iron studies, autoantibodies) plus USS plus FIB-4 sent in one go; recheck LFTs after the modifiable cause is removed
Aetiology-specific management plan offered (lifestyle for MASLD, abstinence for ARLD, drug removal for DILI)
Safety-netting specific (named symptoms: jaundice, confusion, haematemesis, ascites)
Follow-up timeframe explicitly named (8 weeks, not "in a few weeks")

Relating to Others — full criteria

Open question used at outset — let patient lead before directing
ICE all three components explicitly elicited and acknowledged in the plan
Patient's specific concern (cancer, cirrhosis, alcohol) named and directly addressed
Expectation validated before plan offered — "I understand you were hoping for a scan today..."
Motivational language personalised to patient's stated values and relationships
Closing question asked — patient given opportunity to raise remaining concerns

🔴 Red — failing

No diagnosis shared. No safety-netting. Alcohol not addressed. Expectation not elicited. Generic lifestyle advice without patient-specific tailoring. No follow-up plan.

🟠 Amber — borderline

Diagnosis named but not explained. Safety-netting given but vague. Alcohol discussed but not sensitively or specifically. ICE partially explored. Follow-up timeframe given but no contingency for deterioration.

🟢 Green — passing

Diagnosis clearly explained in plain language. All ICE components explicitly addressed in the plan. Safety-netting includes specific named symptoms and emergency route. Alcohol managed sensitively with withdrawal risk acknowledged. Full liver screen with USS and FIB-4. Named follow-up at 8 weeks. Closing question asked. Patient verbalised understanding.

"I got this letter saying my liver blood tests were abnormal and I need to discuss them — to be honest, I am not sure what it all means but it sounds worrying."

Who you are

Tariq Rahman, 49-year-old secondary school PE teacher. BMI 33, waist 101 cm. Known type 2 diabetes on metformin. Taking ibuprofen 400 mg TDS for a knee injury for the past 3 months. Drinks "a few beers" most evenings — actually 20–25 units per week. Lives with wife and two teenage children. Works long hours in a high-stress job.

Hidden agenda

Tariq is genuinely frightened this is cancer — his father died of liver cancer at 58. He has not mentioned this to anyone and plans not to bring it up unless directly asked. He is also concealing his alcohol intake — he knows he drinks more than he should but does not think it is "that much." He is embarrassed about both. He came expecting to be told it is "probably nothing" and sent home.

Symptoms if asked directly

No jaundice, no dark urine, no pale stools
Mild fatigue — attributed to work stress
Some mild RUQ discomfort after eating fatty foods — mentions it if asked specifically
No weight loss, no fever, no confusion
No haematemesis, no melaena

Lifestyle plus bonus details

Diet: takeaways 3–4 nights per week, limited fruit and vegetables, high saturated fat
Exercise: used to be very active but knee injury has stopped all sport for 3 months
Alcohol: 3–4 beers nightly Monday to Friday, more at weekends — approximately 22 units/week. Will disclose accurately only if asked directly and non-judgementally.
Herbal supplements: taking "milk thistle" and "turmeric capsules" for the knee — will not volunteer this; only reveals if specifically asked about supplements

"Look, I am not a big drinker — just a few beers to unwind. Are you saying this is all because of alcohol? My dad had liver cancer and the GP just told him he was drinking too much for years before they actually found it. Are you sure this is not something more serious?"

Resolution: Tariq will engage with the plan if: (1) the GP directly asks about his father's liver cancer and acknowledges his understandable fear — "That must make this result feel much more frightening — your dad's story is really important context for how we approach this"; (2) alcohol is addressed sensitively and without blame, with a clear explanation of why it matters for the investigation; (3) the supplements are asked about specifically (milk thistle and turmeric can cause LFT elevation and are clinically relevant); and (4) a concrete, staged investigation plan is offered with a named follow-up date. If any of these are missed, Tariq will disengage, feel dismissed, and not attend the follow-up appointment.

🏥

Clinic Quick Reference

Abnormal LFTs — Clinical Decision Framework

BSG/BASL 2018 · NICE NG49 · First Presentation or Incidental Finding

▼expand

🚦 1 — Triage System

Abnormal LFT result → Is the patient well or unwell? → Degree of elevation? → Features of decompensation?

↓

🔴 Emergency — 999 / A&E now

Jaundice plus confusion or asterixis (hepatic encephalopathy)
Haematemesis or melaena with known or suspected liver disease (varices)
Charcot's triad: fever plus jaundice plus RUQ pain (ascending cholangitis)
Acute liver failure: INR >1.5 plus encephalopathy (any cause)
Paracetamol OD with raised LFTs (NAC within 8–10 hours)

999 / A&E immediately

🟠 Urgent — same-day or suspected cancer pathway referral

ALT/AST >10× ULN in well patient — same-day GP review
New clinical jaundice without encephalopathy — same-day
New ascites with raised LFTs — same-day referral
Jaundice aged 40+, or weight loss plus raised ALP or abdominal mass — suspected cancer pathway referral / urgent imaging (NG12)
INR >1.2 (not anticoagulated) — same-day review

Same-day review / suspected cancer pathway referral

🟢 Routine — GP primary care

ALT/AST <3× ULN, well patient, likely metabolic
Isolated raised GGT — alcohol or medications
Isolated raised ALP — check GGT (bone vs liver)
MASLD on USS, FIB-4 <1.3, no decompensation

Full liver screen + USS + FIB-4, lifestyle

🔬 2 — Pattern Recognition & Diagnostic Pathway

LFT Pattern → Likely Cause

Hepatocellular (ALT dominant): MASLD, ARLD (AST:ALT >2), viral hepatitis, DILI, AIH, ischaemic

Cholestatic (ALP plus GGT dominant): gallstones/CBD obstruction, PBC, PSC, drugs, pancreatic Ca, biliary stricture

Mixed: DILI (many drugs), infiltrative disease, ARLD

Isolated GGT: alcohol, enzyme inducers, fatty liver, obesity

Isolated ALP (GGT normal): bone origin — Paget's, bony mets, pregnancy

Staged Investigation Approach

1st line (all, in one go): USS + Hep B/C serology, ferritin/transferrin saturation, ANA/AMA/SMA + immunoglobulins, coeliac serology, TFTs, FBC, HbA1c, lipids, INR, albumin

FIB-4: Calculate if MASLD or ARLD — <1.3 GP manage, 1.3–2.67 ELF test, >2.67 hepatology

Recheck LFTs: 4–6 weeks after stopping a drug or alcohol — alongside, not instead of, the screen

Autoimmune screen: ANA, ASMA, AMA, anti-LKM1, IgG/IgM if hepatocellular without clear aetiology

Iron studies: Ferritin + transferrin saturation if haemochromatosis suspected

📊 3 — Key Numbers

>3× ULN

ALT/AST significant elevation requiring 2nd-line investigation

>10× ULN

ALT/AST acute hepatocellular injury, same-day review

4–6 weeks

Recheck LFTs after removing a drug or alcohol — with, not instead of, the screen

FIB-4 <1.3

Low fibrosis risk — manage in primary care

FIB-4 >2.67

High fibrosis risk — hepatology referral (local pathway threshold)

<35 g/L

Albumin — hypoalbuminaemia, hepatic synthetic dysfunction

>1.2 INR

INR (not anticoagulated) — hepatic synthetic dysfunction

AST:ALT >2:1

Supports ARLD with raised GGT and MCV — not diagnostic alone

>45%

Transferrin saturation — haemochromatosis screen positive

14 units/wk

Lower-risk alcohol limit (not a safe limit) — above this, use AUDIT-C

6-monthly

HCC surveillance (USS ± AFP) — all confirmed cirrhosis

>95%

HCV cure rate with direct-acting antivirals (SVR12)

💊 4 — Medication Decision & Choice

Aetiology-Specific Drug Choice

MASLD + T2DM: GLP-1 RA + SGLT-2i for their diabetes/obesity indications (not licensed for MASH; NG49)

MASLD with advanced fibrosis (specialist only, NICE NG49): Pioglitazone or Vitamin E 800 IU

PBC: UDCA 13–15 mg/kg/day (specialist initiated)

AIH: Prednisolone + azathioprine (specialist initiated)

Hep C: Direct-acting antivirals — 8–12 weeks, >95% cure

Hep B: Tenofovir or entecavir (lifelong — specialist)

Haemochromatosis: Therapeutic venesection (specialist)

Ascites (cirrhosis): Spironolactone 100 mg OD + low-sodium diet

Key Prescribing Rules

✓ Statins: SAFE in MASLD and compensated ARLD — do NOT stop for LFT elevation <3× ULN

✓ Metformin: Continue in MASLD and compensated cirrhosis (hold only if AKI or eGFR <30)

✓ Paracetamol: Preferred analgesic; reduce the dose: commonly max 3 g/day with risk factors; some SPCs advise 2 g/day in chronic heavy alcohol use — check the SPC

✗ NSAIDs in cirrhosis: ABSOLUTELY CONTRAINDICATED — AKI, GI bleed, hepatorenal syndrome

✗ UDCA in primary care: Do NOT start without confirmed PBC diagnosis from hepatology

✗ Herbal supplements: Stop ALL during LFT investigation — frequent unrecognised DILI cause

⚠ 5 — Safety Netting & Follow-Up

Follow-up timeline

8 weeks: Liver screen + USS review + repeat LFTs + FIB-4 calculation

3 months: USS results review + fibrosis stratification + referral decision if FIB-4 >2.67

6 months: Metabolic reassessment (HbA1c, lipids, BP, weight) + pharmacotherapy review

12 months: Metabolic/CV review; fibrosis reassessment every 2–3 years if low risk; HCC surveillance if cirrhosis

Ongoing: Shared care with hepatology if advanced disease

📌 Add to chronic disease register — patients not on a recall list are lost to follow-up

🔬 6 — Monitoring & Red Flags

Parameter	Test	Timing	Action threshold
All LFT abnormalities	Full liver screen + USS, then repeat LFTs	Screen at first visit; LFTs 4–6 weeks after any change	Persists → hepatology with the full screen. Normalised → monitor 6-monthly for 12 months.
MASLD / ARLD fibrosis	FIB-4 calculation	Every 2–3 years if low risk	FIB-4 >2.67 → hepatology referral. 1.3–2.67 → ELF test. <1.3 → GP manage.
Cirrhosis HCC	USS ± AFP	6-monthly	New focal lesion or rising AFP → urgent hepatology/radiology review via the local HCC pathway.
Synthetic function	INR + albumin	6-monthly if liver disease	INR >1.2 (not anticoagulated) or albumin <35 → consider non-hepatic causes; if hepatic, urgent hepatology referral.
Portal hypertension	FBC (platelets)	6–12 monthly	Platelets ≤150 × 10⁹/L (or liver stiffness ≥20 kPa) → hepatology referral + OGD variceal screening (Baveno VII).
Hepatitis C on DAAs	HCV RNA	End of treatment + 12 wks post	SVR12 (undetectable RNA 12 weeks post-treatment) = cure.

🚨 Emergency red flags: Jaundice + confusion (encephalopathy), haematemesis/melaena (varices), RUQ pain + fever + jaundice (cholangitis), rapid ascites, INR >1.5 + any encephalopathy → 999

🛡️ Safeguarding: ARLD with young children at home (Children Act 1989), concealed alcohol + domestic abuse signals, paracetamol OD (self-harm) presenting as acute LFT elevation, older adult malnutrition + raised LFTs (neglect)

🎓

SCA Exam Quick Reference

SCA Consultation Blueprint

Tasks · Relating to Others · Global Skills · RAG guide

▼expand

🕐 12-Minute Consultation Flow — with Domain Scoring

0–2 min

Open & Elicit ICE

"Before I go through the results, what has been on your mind since you got that message?"

Reference the result from the notes. Elicit all three ICE components before moving to targeted history.

Relating to OthersGlobal Skills

✗ Jumping straight to "So your ALT is 87..." · ✗ Asking about results the GP already has · ✗ Not asking what they thought was causing it

2–6 min

Targeted History

"Can I ask about your drinking — in a typical week, how many days and how much?"

Must cover: alcohol (quantified), medications + supplements (including herbal), red flag symptoms, viral hepatitis risk, metabolic history, psychosocial context. Data gathering complete by 6–7 minutes.

TasksGlobal Skills

✗ Not asking about alcohol · ✗ Missing supplements and herbal remedies · ✗ Not asking about red flag symptoms

6–8 min

Explain Diagnosis

"The most likely explanation, given your weight, blood sugar, and the ibuprofen, is that your liver is under some extra strain — think of it like a filter that has been working overtime."

Name the most likely cause. Address the cancer fear if expressed or signalled. Use an analogy. Explicitly address hidden concern.

TasksRelating to Others

✗ Using technical terms without explanation · ✗ Not naming a working diagnosis · ✗ Not addressing the cancer fear

8–10 min

Management Plan

"What I would like to do is send a full set of liver blood tests today — including hepatitis and iron levels — arrange a liver scan and work out a scarring score, and in the meantime I would like to talk about what you can do that will genuinely help."

Name: full liver screen (hepatitis serology, iron studies, autoantibodies), USS and FIB-4 now; recheck LFTs after stopping ibuprofen and supplements. Lifestyle advice specific and tailored. Alcohol addressed specifically.

TasksRelating to OthersGlobal Skills

✗ Vague follow-up plan · ✗ Not mentioning FIB-4 · ✗ Generic lifestyle advice · ✗ Prescribing specialist-only treatments

10–12 min

Safety-Net & Close

"If you notice yellowing of your skin, become confused, vomit blood, or your abdomen swells — call 999 immediately. Otherwise, we will see you in 8 weeks."

Summarise collaboratively. Ask: "Does that all make sense?" Closing question: "Is there anything else on your mind?"

TasksRelating to OthersGlobal Skills

✗ Vague safety-net ("if you get worse") · ✗ No closing question · ✗ Not confirming patient understands the plan

🔴🟠🟢 RAG Scoring — All 3 Domains

Tasks Domain

🟢

Working diagnosis named with cause linked to patient history. Staged investigation plan (full liver screen, USS, FIB-4). Aetiology-specific management. Named safety-net symptoms. Follow-up explicitly "8 weeks."

🟠

Diagnosis named but not explained. Investigation plan incomplete (FIB-4 not mentioned). Safety-netting vague. Follow-up mentioned but timeframe not specified.

🔴

No diagnosis offered. No investigation plan. Safety-netting absent. Alcohol not addressed. Red flags not assessed.

Relating to Others

🟢

Open question leads. Full ICE all three components named and addressed in plan. Cancer fear addressed directly. Alcohol explored sensitively. Motivational language personalised. Closing question asked.

🟠

ICE partly explored (usually Ideas only). Cancer fear not named. Alcohol asked but not sensitively. Motivational language generic. Plan announced not negotiated.

🔴

No ICE. No open question. Alcohol not asked. Patient concern not acknowledged. Technical language throughout without translation.

Global Skills

🟢

Data gathering complete by 6–7 minutes. Plain English throughout. Logical structure. Responsive to cues. Checks understanding. Non-judgemental.

🟠

History takes too long (>8 minutes). Some technical language unaddressed. Cues acknowledged but not explored fully.

🔴

Unstructured history. Jargon used without explanation. Cues ignored. No check of understanding. Judgemental about alcohol or lifestyle.

💬 Key Phrases — ICE, Diagnosis & Plan

Ideas

"When you found out the liver tests were abnormal, what did you think might be causing it?"

Concerns

"What is your biggest worry about this result? A lot of people worry it could be something serious — is that something that has crossed your mind?"

Expectations

"What were you hoping we might do today, or what were you expecting might happen next?"

Validate (cancer fear)

"That must make this result feel much more frightening — your father's story is completely understandable context for why you are worried. Let me explain what we are looking at."

Explain (plain language)

"Think of your liver like a processing factory — the tests suggest the factory is under strain, not broken. We have found this early, when we can still do something about it."

"To summarise — we will send the full liver blood tests including hepatitis and iron, arrange a scan and review in 8 weeks, and in the meantime the most important thing is reducing the ibuprofen and cutting back on alcohol. Does that all make sense? Is there anything else on your mind?"

🚫 9 Danger Zones — Instant Deductions

✗

Asking for results the GP already has→ Use existing information: "I can see from the notes that your ALT is 87 — can I ask what you know about what that means?"

✗

Not asking about alcohol when LFTs are raised→ Always ask, always quantify in units, always do so non-judgementally — "I ask everyone about this"

✗

Not asking about herbal supplements and OTC products→ "Medications" alone is insufficient — ask specifically about supplements, herbals, and anything bought online

✗

Vague safety-netting ("come back if worse")→ Name specific symptoms: jaundice, confusion, haematemesis, abdominal swelling — call 999, not the surgery

✗

Not addressing the cancer concern when signalled→ Name it: "I think you might be worried this could be something like cancer — let me address that directly"

✗

Starting UDCA or corticosteroids in primary care without confirmed diagnosis→ "Once the specialist confirms the diagnosis, they will start the appropriate treatment and we will monitor you here"

✗

Stopping statins for mild LFT elevation→ Statins are safe in liver disease; stopping increases CVD mortality. Continue unless >3× ULN and attributable to statin.

✗

Advising abrupt cessation of alcohol without warning about withdrawal→ "If you are drinking heavily, stopping suddenly can be dangerous — please let us help you do this safely to avoid withdrawal"

✗

Not mentioning FIB-4 in MASLD or ARLD→ FIB-4 is the first-line non-invasive fibrosis test in primary care in the BSG/BASL 2018 guideline — naming it demonstrates current clinical knowledge and scores Tasks marks

💊 Drug Quick-Pick by Scenario

MASLD plus T2DM (BMI >27)

→Semaglutide 2.4 mg SC/wk

Weight loss is first-line; GLP-1 has off-label MASH benefit. Add SGLT-2i (empagliflozin) in T2DM for cardiorenal protection. Resmetirom is the first MASH-specific agent (not UK-licensed; technology appraisal ID6529 in progress).

MASLD with advanced fibrosis (secondary/tertiary care only)

→Pioglitazone 30–45 mg OD

Specialist, off-label decision (NICE NG49) — not a primary-care MASLD drug. Contraindicated in heart failure, bladder cancer and unexplained visible haematuria.

Cirrhosis with ascites

→Spironolactone 100 mg OD

Add furosemide 40 mg if insufficient. Low-sodium diet (<2g/day). Monitor U&E weekly initially. NSAIDs absolutely contraindicated.

Hepatitis C (any genotype)

→Sofosbuvir/velpatasvir 8–12 wks

>95% cure rate. Check drug interactions (SPC). HCV RNA at end of treatment plus 12 weeks post = SVR12 (cure).

Primary Biliary Cholangitis (PBC confirmed)

→UDCA 13–15 mg/kg/day

Specialist-initiated only. GP prescribes on shared care. Specialist assesses response at 12 months (ALP ≤1.67× ULN and normal bilirubin).

Drug-induced liver injury (DILI confirmed)

→Stop offending drug immediately

RUCAM causality assessment. Yellow Card reporting. Recheck LFTs in 1 week. If >3× ULN persists after 4 weeks → hepatology phone advice. No rechallenge without specialist input.

⛔ Never start UDCA without confirmed PBC diagnosis | Never advise abrupt alcohol cessation without withdrawal assessment | Never stop statins for LFT elevation <3× ULN | NSAIDs absolutely contraindicated in cirrhosis | Do not initiate corticosteroids for AIH without histological confirmation | Always ask about herbal supplements — not just "medications"

Abnormal Liver Function Tests · GP Clinical Reasoning Framework v2 · NICE CG165 (chronic hepatitis B, 2013, updated 2017) · NICE NG49 (MASLD, formerly NAFLD; updated July 2026) · BSG 2018 abnormal LFT guideline · NICE TA875 (semaglutide for weight management) · EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B and C (2017/2020) · BSG/BASL Guidelines on the management of abnormal liver blood tests (2017) · AASLD/EASL MASLD Guidelines (2023)

v3: Dual tailored summaries (Clinic + SCA) with visual algorithms · v2: Clinical stem · Open Q first · ICE in all modes · Psychosocial (1E + 7G) · Lay language DDx (Step 5) · Safeguarding (Step 1) · Expectation management (7A) · SCA RAG checkpoints after every step · SCA Scorecard as standalone section

Teaching clinicians why each step matters — not just what to do · Always consult current SPC and local formulary · Clinical judgement takes precedence over any framework · Liver disease is the only major cause of premature mortality in the UK still rising — find it early.

Abnormal LFTs

Red Flags — act before continuing history

Safeguarding Considerations — Consider in Every Consultation

🏠 Domestic Abuse / Intimate Partner Violence

👴 Older Adults / Carer-related Concern

🧒 Children in the Household

💊 Self-Harm / Substance Misuse Risk

🍷 Alcohol and Stress

🏙️ Socioeconomic Deprivation

🧠 Mental Health Comorbidity

👪 Family and Social Support

🏢 Work and Occupation

🌎 Cultural and Ethnic Background

999 or Same-Day Hospital

Same-Day GP / Urgent Assessment

Manage in Primary Care

Autoimmune Hepatitis (AIH)

Primary Biliary Cholangitis (PBC)

Hereditary Haemochromatosis

MASLD with Advanced Fibrosis (FIB-4 >2.67)

Chronic Viral Hepatitis B or C

Acute Liver Failure

Ascending Cholangitis

Hepatocellular Carcinoma / Biliary Malignancy

Variceal Bleeding

Validate — name their expectation

Explain — share your clinical reasoning

Negotiate — offer something today

Driving

Work and Employment

Relationships and Disclosure

Physical Activity and Daily Life

Alcohol and Social Life

Insurance and Legal Implications

8 weeks — Review the liver screen, USS and FIB-4, plus repeat LFTs

3 months — Liver USS results plus fibrosis stratification plus medication review

6 months — Glycaemic and metabolic reassessment plus lifestyle progress review

12 months — Annual liver disease review (GP chronic disease register)

Ongoing — Specialist-shared care model if advanced disease

Memory rule

⚠ Three scenario-specific phrases — use these verbatim

Why safety-netting matters beyond clinical care

🎭 Patient actor brief — click to practise

Who you are

Hidden agenda

Symptoms if asked directly

Lifestyle plus bonus details